MILES TO GO

THE RESPONSE TO HIV
IN ASIA AND THE PACIFIC



Contents

Asia and the Pacific	2
Australia	12
Bangladesh	14
Cambodia	16
India	18
Indonesia	20
Japan	22
Lao People's Democratic Republic	24
Malaysia	26
Mongolia	28
Myanmar	30
Nepal	32
New Zealand	34
Pakistan	36
Papua New Guinea	38
Philippines	40
Singapore	42
Sri Lanka	44
Thailand	46
Viet Nam	48
Annoy on mothods	5 1

Asia and the Pacific

AT A GLANCE

The HIV epidemic is not over yet: some countries in the region are on track to meet the Fast-Track Targets, but epidemics are expanding in Pakistan and Philippines.


While strong progress has been made in increasing access to life-saving HIV treatment, access to HIV prevention services for members of key populations and their intimate partners continue to lag.

Rising incidence of HIV among gay men and other men who have sex with men could lead to rebounding HIV epidemics in several countries in the region.

Some countries with comprehensive harm reduction programmes have reduced new HIV infections among people who inject drugs, but access to harm reduction services is still not adequate across the region.

Active and well-supported community involvement is crucial for the success of the HIV response in the region.

Percent change in new HIV infections between 2010 and 2017 and the proportion of new HIV infections that were among young people aged 15–24 years in 2017, Asia and the Pacific



Source: UNAIDS 2018 estimates

Asia and the Pacific has made strong inroads with its HIV response. Sustained and focused efforts to reach key populations have led to major reductions in HIV infections in Cambodia, India, Myanmar, Thailand and Viet Nam between 2010 and 2017. However, epidemics are expanding in Pakistan and Philippines.

The vast majority of new HIV infections in Asia and the Pacific are associated with current or former members of key populations and their partners. Unprotected sex between men—especially young men—is an increasingly important factor in many of the region's HIV epidemics: epidemics among gay men and other men who have sex with men are expanding in several countries. Key populations must remain at the core of HIV prevention.

HIV risk among young people within key populations is of particular concern: since 2010, new HIV infections among young people (aged 15–24 years) increased by 170% in Philippines and 29% in Pakistan.


1

2


2


4

EPIDEMIC TRANSITION MEASURES



New HIV infections in Asia and the Pacific decreased by 14% during 2010–2017 and annual deaths from AIDS-related illness declined by 39% during that same period. The combined progress reduced the region's incidence:prevalence ratio to a comparatively low 0.05 [0.04–0.08] in 2017; it is steadily moving towards the 0.03 epidemic transition benchmark. Slower progress on HIV prevention compared to treatment translates to steadily increasing numbers of people living with HIV and rising costs for HIV-related health care.





LAWS AND POLICIES SCORECARD

Country	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Drug use or possession for personal use an offence	Parental consent for adolescents to access HIV testing	Spousal consent for married women to access SRH services	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Afghanistan									
Australia			a						
Bangladesh									
Bhutan									
Brunei-Darussalam									
Cambodia					Ь				
China									
Cook Islands									
Democratic People's Republic of Korea									
iji									
ndia									
ndonesia									
apan									
(iribati									
ao People's Democratic Republic									
⁄lalaysia									
Maldives									
Marshall Islands									
Aicronesia (Federated States of)									
Mongolia									T
		••••				•••			
	Criminalized and/or prosecuted Neither criminalized nor prosecuted Data not available	Any criminalization or punitive regulation of sex work Sex work is not subject to punitive regulations or is not criminalized Issue is determined/differs at subnational level Data not available	Death penalty Imprisonment (14 years-life, up to 14 years) or no penalty specified Data not available	Compulsory detention for drug offences Possession of drugs for personal use is specified as a non-criminal offence Data not available	Yes, for adolescents younger than 18 Yes, for adolescents younger than 14 and 16 Yes, for adolescents younger than 12 No Data not available	Yes No Data not available	Yes No, but prosecutions exist based on general criminal laws No Data not available	Yes No Data not available	Yes No No Data not available

^a Australia. Marriage Amendment (Definition and Religious Freedoms) Act 2017. Sec 2CA (https://www.legislation.gov.au/Details/C2017A00129). ^b Kingdom of Cambodia. The Law on the Prevention and Control of HIV/AIDS. No. NS/RKM/0702/015. 1 August 2002.

Note: Data on laws restricting the entry, stay and residence of people living with HIV are currently undergoing a global review that will involve country validation. An update is expected by the end of 2018.


Sources: National Commitment and Policy Instrument, 2017 and 2018; supplemented by additional sources where noted.

Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Drug use or possession for personal use an offence	Parental consent for adolescents to access HIV testing	Spousal consent for married women to access SRH services	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
		С						
secuted secuted secuted wailable	ex work inalized nal level vailable	penalty pecified vailable	offences loffence vailable	than 18 tand 16 than 12 No vailable	Yes No Nailable	Yes nal laws No	Yes No Nailable	Yes No No Nailable
Criminalized and/or pros Neither criminalized nor pros	Any criminalization or punitive regulation of st. ot subject to punitive regulations or is not crimilissue is determined/differs at subnation.	Death (14 years-life, up to 14 years) or no penalty st	Compulsory detention for drug o drugs for personal use is specified as a non-criminal	Yes, for adolescents younger: Yes, for adolescents younger than 14 Yes, for adolescents younger! Data not av	Data not av	. but prosecutions exist based on general crimir Data not av	Data not av	Yes No Data not evallable


cIndependent State of Samoa. Crimes Act 2013, No. 10. Sec 67 (http://www.palemene.ws/new/wp-content/uploads//01.Acts/Acts%202013/Crimes_Act_2013_-_Eng.pdf).

STIGMA AND DISCRIMINATION

Percentage of men and women aged 15–49 years who would not buy vegetables from a shopkeeper living with HIV, Asia and the Pacific, 2000–2016




Percentage of people living with HIV who experienced discrimination in healthcare settings, countries with available data, Asia and the Pacific, 2014–2017




Health-care professional ever told other people about their HIV status without their consent

Source: People Living with HIV Stigma Index surveys, 2014–2017.

Percentage of key populations who reported having avoided health-care services and HIV testing in the past 12 months due to stigma and discrimination, countries with available data, Asia and the Pacific, 2014–2017



Percentage of ever-married or partnered women aged 15–49 years who experienced physical and/or sexual violence by an intimate partner in the past 12 months, countries with available data, Asia and the Pacific, 2012–2016



Source: Population-based surveys, 2012–2016


Successive surveys in Cambodia, India, Thailand and Viet Nam indicate that attitudes towards people living with HIV have improved. At the same time, 50% or more of people surveyed in Afghanistan, Indonesia, Mongolia, Myanmar, Pakistan and Timor-Leste said they would not buy vegetables from a vendor living with HIV (1).

While several countries in the region have earned plaudits with their HIV programmes for female sex workers, stigma and discrimination still poses a major barrier in places like Fiji, where more than half (59%) of female sex workers reported avoiding health-care services due to stigma and discrimination. In Lao People's Democratic Republic and Thailand, by contrast, only 2% and 11% of female sex workers, respectively, reported similar trepidation (1). Three quarters (75%) of gay men and other men who have sex with the men in Lao People's Democratic Republic and about one third (36%) of their peers in Fiji said that stigma and discrimination deterred them from visiting health-care facilities (2).

More than a quarter of women reported being physically or sexually assaulted by an intimate partner in the previous 12 months in Afghanistan, Bangladesh, Nauru and Timor-Leste (3). One in five transgender women in India experienced sexual violence in the last 12 months, and one quarter of transgender women in Bangladesh reported being raped in the last 12 months (4).

COMBINATION HIV PREVENTION

Availability of pre-exposure prophylaxis for key populations through pilot projects and demonstration sites, Asia and the Pacific, March 2018



Source: 2017 and 2018 National Commitments and Policy Instrument. Information based on communications with national HIV programmes and UNAIDS country offices in Asia and the Pacific, 2017.


While several countries have successfully reduced HIV transmission during sex work, the region has had less success in reversing the HIV epidemics among gay men and other men who have sex with men. Coverage of prevention programmes for this population are low, and services tend to be focused chiefly in large cities. There has been an encouraging increase in the number of countries offering pre-exposure prophylaxis (PrEP), albeit mainly through pilot projects and at demonstration sites. By March 2018, PrEP was available on a limited basis to gay men and other men who have sex with men in China, India, Malaysia, New Zealand, Philippines, Thailand and Viet Nam¹. In Australia, PrEP is being provided at scale.

When harm reduction programmes have been provided at scale in Asia and the Pacific, they have led to declines in HIV prevalence among people who inject drugs (such as in Malaysia). Fourteen countries across Asia were implementing needle–syringe programmes in 2016, but very few of them have expanded their programmes in recent years (5).

¹Information based on communication with national HIV programmes and UNAIDS country offices in Asia and the Pacific, 2017.

HIV TESTING AND TREATMENT

HIV testing and treatment cascade, Asia and the Pacific, 2017



Source: UNAIDS special analysis, 2018; see annex on methods for more details.


Among the 5.2 million [4.1–6.7 million] people living with HIV in Asia and the Pacific at the end of 2017, 74% [52–>95%] were aware of their HIV status, an increase from 70% [49–94%] in 2016. The gap to achieving the first 90 of the 90–90–90 targets in 2017 was 816 000 people living with HIV.

About 2.7 million [2.4–2.9 million] people in the region were accessing antiretroviral therapy in 2017, or 53% [37–72%] of all people living with HIV. The gap to achieving the first and second 90s of the 90–90–90 targets in 2017 was 1.5 million people living with HIV.

The estimated percentage of people living with HIV who achieved viral suppression increased from 38% [27–52%] in 2016 to 45% [31–61%] in 2017. The gap to achieving all three 90s in 2017 was the testing, treatment and viral suppression of an additional 1.4 million people living with HIV.

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION


Cascade of services for preventing vertical transmission and transmission rate, Asia and the Pacific, 2017



Although decreasing, the rate of mother-to-child transmission of HIV in Asia and the Pacific remains comparatively high—17% in 2017. Programme coverage has more than doubled since 2010, but it remains among the lowest in the world. Only about half (56%) of the estimated 61 000 women living with HIV who gave birth in the region in 2017 received effective antiretroviral prophylaxis in 2017. Only a quarter of HIV-exposed infants received early infant diagnosis.

INVESTMENT

HIV resource availability by source, 2006–2017 and projected resource needs by 2020, Asia and the Pacific



*Estimates for low- and middle-income countries per 2015 World Bank income level classification. All figures are expressed in constant 2016 US dollars. Source: UNAIDS 2018 resource availability and needs estimates.

In total, an estimated US\$ 3.7 billion was available in 2017 for the AIDS response in Asia and the Pacific. Financial resource availability in Asia and the Pacific has increased by 76% since 2006. While domestic resources have doubled over the last decade, a global shift in donor priorities towards countries with large disease burdens has contributed to a 30% decline in international funding for HIV programmes in the region. A 25% overall increase in resources is needed by 2020 to reach the region's Fast-Track resource target of US\$ 4.9 billion. Domestic resources comprised 78.4% of total HIV investments. The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) and the United States President's Emergency Plan for AIDS Relief (PEPFAR) contributed 7.3% and 4.1%, respectively.

References

- 1. Population-based surveys, 2012–2017.
- 2. Integrated biological and behavioural surveys, 2014–2017.
- 3. Population-based surveys, 2012–2016.
- 4. Integrated biological and behavioural surveys, 2014–2016.
- 5. Global state of harm reduction 2016. London: Harm Reduction International: 2016.

AUSTRALIA

		2010	2017
New HIV infections			
New HIV infections (all ages)	860	930	1000
	[690–970]	[750–1100]	[800–1100]
New HIV infections (0–14)			
	[–]	[]	[]
New HIV infections (women, 15+)	<100	<100	<200
	[<100– <200]	[<100– <200]	[<100- <200]
New HIV infections (men, 15+)	770	830	900
	[590–880]	[650–960]	[690–1000]
HIV incidence per 1000 population	0.04 [0.03–0.05]	0.04 [0.03–0.05]	0.04 [0.03–0.05]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<200
	[<200– <500]	[<200– <500]	[<100-<500]
AIDS-related deaths (0-14)			
	[–]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<500	<500	<200
	[<200– <500]	[<200– <500]	[<100- <500]
People living with HIV			
People living with HIV (all ages)	16 000	20 000	26 000
	[14 000–19 000]	[18 000–23 000]	[23 000–29 000]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	1500	2000	2700
	[1300–1700]	[1700–2200]	[2500–3000]
People living with HIV (men, 15+)	15 000	18 000	23 000
	[13 000–17 000]	[16 000–21 000]	[20 000–27 000]

Laws criminalizing the transmission of, nondisclosure of or exposure to HIV transmission

Criminalization of sex work

Criminalization of same-sex sexual acts

Criminalization of transgender people

Laws penalizing same-sex sexual acts have been decriminalized or never existed

Drug use or possession for personal use is an offence

Laws or policies restricting the entry, stay and

residence of people living with HIV Parental consent for adolescents to access HIV

Spousal consent for married women to access sexual and reproductive health services

Mandatory HIV testing for marriage, work or residence permits or for certain groups

Percentage of women and men aged 15-49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


Fina	ancing sources			
		International: Global Fund	International: all others	


Last available report: 2006 US\$ 101 415 112 US\$ 101 415 112


testing

8%









Change in new HIV infections since 2010

related deaths since 2010

Incidence: prevalence ratio

-53%

0.04


KEY POPULATIONS

KETTOTOE (HOTS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population		263 530	79 055		38 845
HIV prevalence		18.3%	1.7%		
Know their HIV status					
Antiretroviral therapy coverage		78%			
Condom use		38.3%	31.9%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	29 [25–34]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed	
Alleres	%	82%	%	
All ages	[%]	[73–93%]	[%]	
Children (0. 1/	%	%	%	
Children (0-14	[%]	[%]	[%]	
Women (15+)	%	94%	%	
women (15+)	[%]	[85->95%]	[%]	
Mon (15+)	%	81%	%	
Men (15+)	[%]	[71–92%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years

— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Early infant diagnosis	%	%


Harm reduction


 Use of sterile injecting equipment at last injection (2015) 	74%
 Needles and syringes distributed per person who injects (2016) 	624.88
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	
— Safe injection rooms available (2016)	


BANGLADESH


EPIDEMIC ESTIMATES				
	2005	2010	2017	
New HIV infections				
New HIV infections (all ages)	1700 [1500–1900]	1500 [1400–1700]	1700 [1500–1800]	
New HIV infections (0–14)	<100 [<100- <100]	<100 [<100-<100]	<100 [<100–<100]	
New HIV infections (women, 15+)	<500 [<500- <500]	530 [<500–600]	520 [<500–590]	
New HIV infections (men, 15+)	1200 [1100–1300]	930 [830–1100]	1100 [990–1200]	
HIV incidence per 1000 population	0.01 [0.01–0.01]	0.01 [<0.01–0.01]	0.01 [<0.01–0.01]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<500 [<500- <500]	880 [720–1100]	1100 [930–1200]	
AIDS-related deaths (0–14)	<100 [<100- <100]	<100 [<100-<100]	<100 [<100-<100]	
AIDS-related deaths (women, 15+)	<100 [<100–<100]	<500 [<200– <500]	<500 [<500–<500]	
AIDS-related deaths (men, 15+)	<500 [<200– <500]	630 [520–760]	690 [610–780]	
People living with HIV				
People living with HIV (all ages)	6400 [5800–7100]	10 000 [9100–12 000]	13 000 [11 000–15 000]	
People living with HIV (0–14)	<100 [<100- <100]	<200 [<200– <500]	<500 [<500–<500]	
People living with HIV (women, 15+)	1500 [1300–1700]	3200 [2800–3600]	4400 [3800–5000]	
People living with HIV (men, 15+)	4800 [4300–5400]	7000 [6100–8100]	8500 [7300–9900]	
LAWS AND POLICIES		STIGMA AND DISCR	RIMINATION	
Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	No	Percentage of women and men	•	2013
Criminalization of sex work	Partial criminalization of sex work	towards people living with HIV	y attitudes	34.6*
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2017 5
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence	Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		2017
Criminalization of transgender people	Neither criminalized nor prosecuted			5
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HI ^t testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or p women aged 15–49 years who e		2015
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months		28.8
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No	*Female respondents only		

EXPENDITURES					
		Fin	ancing sources		
Last available report: 2017	US\$ 1286	US\$ 311 024		US\$ 6 099 087	 US\$ 7 103 747









Change in new 10% HIV infections since 2010

Change in AIDS-related deaths since 2010

20%

Incidence: prevalence ratio

0.13


$K \vdash V$	P() P		
	1 () [\cup	FIONS

RETTOTOE MICH					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	139 961	101 695	33 066	10 199	73 433
HIV prevalence	0.2%	0.2%		1.4%	
Know their HIV status	31.2%			35.1%	
Antiretroviral therapy coverage	78.3%	53.9%	30.9%	66.7%	
Condom use	66.7%	45.8%	34.9%	41.1%	
Coverage of HIV prevention programmes	15.2%	4.4%	27.8%	15.2%	
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	500 [250–840]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	11.4%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed
Allana	35%	19%	%
All ages	[31–41%]	[16–22%]	[–%]
Children (0-14)	81%	37%	%
	[71–94%]	[32–42%]	[–%]
Women (15+)	34%	19%	%
	[30–39%]	[16–21%]	[%]
Men (15+)	34%	18%	%
	[30-40%]	[16–21%]	[%]

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

treatment

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years (2014)

— Women	12.7%
— Men	•••
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	•••
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2014)	72.6%

Men aged 15–49 years who are circumcised	applicable	
Male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2017)		

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	14%	17%
accessing antiretroviral medicines	[11–16%]	[15–21%]
Early infant diagnosis	2%	14%
Early Illiant diagnosis	[2_3%]	[12_16%]

Harm reduction

 Use of sterile injecting equipment at last injection (2015) 	83.9%
 Needles and syringes distributed per person who injects (2017) 	125.36
 Coverage of opioid substitution therapy (2017) 	2.6%
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No

CAMBODIA


EPIDEMIC ESTIMATES					
	2005	2010	2017		
lew HIV infections					
lew HIV infections (all ages)	3800 [3400–4200]	1600 [1400–1800]	590 [530–650]		
lew HIV infections (0–14)	720 [600–890]	<500 [<500–<500]	<100 [<100- <200]		
lew HIV infections (women, 15+)	1900 [1700–2100]	700 [610–770]	<500 [<500–<500]		
ew HIV infections (men, 15+)	1200 [1100–1300]	540 [<500–600]	<500 [<500-<500]		
IV incidence per 1000 population	0.29 [0.26–0.31]	0.11 [0.1–0.12]	0.04 [0.03–0.04]	
IDS-related deaths					
IDS-related deaths (all ages)	7400 [6400–8300]	2300 [1400–3700]	1300 [1000–1900]		
IDS-related deaths (0–14)	<500 [<500–590]	<200 [<200–<500]	<100 [<100– <100]		
NIDS-related deaths (women, 15+)	2700 [2300–3100]	810 [<500–1300]	590 [<500–930]		
AIDS-related deaths (men, 15+)	4200 [3700–4900]	1300 [690–2200]	710 [540–980]		
eople living with HIV					
eople living with HIV (all ages)	87 000 [72 000–110 000]	78 000 [67 000–93 000]	67 000 [58 000–79 000]	
eople living with HIV (0-14)	4700 [4100–5600]	5100 [4300–6000]	3300 [2700–4200]		
eople living with HIV (women, 15+)	38 000 [33 000–46 000]	37 000 [32 000–44 000]	34 000 [30 000–39 000]	
eople living with HIV (men, 15+)	44 000 [34 000–56 000]	36 000 [30 000–44 000]	30 000 [25 000–35 000	l	
AWS AND POLICIES		STIGMA AND DIS	CRIMINATION	1	
aws criminalizing the transmission of, non- lisclosure of or exposure to HIV transmission	Yes	Percentage of women and years who report discrimin		2005	201
Criminalization of sex work	Other punitive regulation of sex work	towards people living with		31.8	19.4
riminalization of same-sex sexual acts	No specific legislation	Percentage of people living health services because of the last 12 months			
rug use or possession for personal use is an ffence		Percentage of people living reported a health-care prof			
riminalization of transgender people	Neither criminalized nor prosecuted	about their HIV status with			
aws or policies restricting the entry, stay and esidence of people living with HIV	No	VIOLENCE			
arental consent for adolescents to access HI esting	Yes, for adolescents younger than 18 years	Proportion of ever-married women aged 15–49 years v	the state of the s	2005	201
pousal consent for married women to access exual and reproductive health services	No	physical or sexual violence intimate partner in the past	e from a male	9	10.9


EXPENDITURES						
		Fin	ancing sources			
Last available report: 2012	US\$ 956 837	US\$ 5 212 931		US\$ 20 211 071	US\$ 20 182 528	US\$ 50 883 717


Mandatory HIV testing for marriage, work or


residence permits or for certain groups

No









Change in new **HIV** infections since 2010

-63%

related deaths since 2010

Incidence: prevalence ratio

0.01

0.34

KEY POPULATIONS

KETT OF GEATIONS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	34 000	20 000		3 000	17 522
HIV prevalence		2.3%	15.2%		
Know their HIV status		70.4%		70.9%	
Antiretroviral therapy coverage	82.8%	95.4%	30.8%	95.1%	
Condom use	88.8%	69.4%	8.7%	62.6%	
Coverage of HIV prevention programmes		69.4%	78%		
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis 1300 cases among people living with HIV (2016) [850-1900]


enrolled in HIV care with active tuberculosis (2016)Cervical cancer screening of women living with HIV

Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment

Proportion of people living with HIV newly

Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment

HIV TESTING AND TREATMENT CASCADE



All ages	88%	87%	83%
	[76– >95%]	[75– >95%]	[72– >95%]
Children (0-14)	>95%	>95%	86%
	[87– >95%]	[83->95%]	[71– >95%]
Women (15+)	89%	88%	85%
	[78– >95%]	[77– >95%]	[75– >95%]
Men (15+)	85%	84%	81%
	[72– >95%]	[71– >95%]	[68–94%]

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years (2014)

, , , , , , , , , , , , , , , , , , ,	
— Women	37.6%
— Men	45.9%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner) (2014)	

— Women 41.5% 72.8% — Men

Women aged 15-49 years who have their demand for family planning satisfied by 56.5% modern methods (2014)

Not Men aged 15-49 years who are circumcised applicable Male circumcisions performed according to Not national standards applicable People who received PrEP at least once during the reporting period (2017)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	34%	>95%
accessing antiretroviral medicines	[28-40%]	[73->95%]
Early infant diagnosis	45%	64%
Early Illiant diagnosis	[39-54%]	[55-85%]

Harm reduction


 Use of sterile injecting equipment at last injection (2017) 	93.5%
 Needles and syringes distributed per person who injects (2017) 	304.64
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	Yes
— Safe injection rooms available (2016)	No


INDIA


	2005	2010	2017		
	2005	2010	2017		
ew HIV infections					
ew HIV infections (all ages)	130 000	120 000	88 000		
, , ,	[66 000–230 000]	[60 000–210 000]	[44 000–160 0	000]	
ew HIV infections (0–14)	13 000	7700	3700		
	[8100–20 000]	[4800–12 000]	[2300–5800]		
ew HIV infections (women, 15+)	48 000	45 000	34 000	201	
	[23 000–87 000]	[22 000–81 000]	[16 000–60 00	00]	
ew HIV infections (men. 15+)	71 000	67 000 50 000			
	[35 000–130 000]	[33 000–120 000]	[25 000–92 00	00]	
V incidence per 1000 population	0.12 [0.06–0.22]	0.1 [0.05–0.18]	0.1 [0.03–0.12	2]	
DS-related deaths					
	240 000	160 000	69 000		
DS-related deaths (all ages)	[110 000–440 000]	[76 000–290 000]	[34 000–130 0	0001	
	11 000	6800	2600		
DS-related deaths (0–14)	[5900–19 000]	[3700–12 000]	[1400–4600]		
	88 000	58 000	20 000		
DS-related deaths (women, 15+)	[38 000–180 000]	[25 000–120 000]	[8800–42 000	1	
			-	J	
DS-related deaths (men. 15+)	140 000	91 000	46 000	001	
	[68 000–250 000]	[45 000–170 000]	[23 000–84 00	00]	
eople living with HIV			0.400.000		
eople living with HIV (all ages)	2 800 000	2 300 000	2 100 000	000 0001	
	[2 000 000–3 900 000]	[1 700 000–3 300 000]	[1 500 000–3	000 000]	
eople living with HIV (0–14)	100 000	88 000	61 000		
	[71 000–150 000]	[61 000–130 000]	[42 000–88 00	00]	
eople living with HIV (women, 15+)	1 100 000	900 000	880 000		
opio irriig iriti irri (iroinoii, 10-1)	[760 000–1 500 000]	[650 000–1 300 000]	[630 000–1 200 000]		
eople living with HIV (men, 15+)	1 600 000	1 300 000 1 200 000			
sopio nung marrin (mon, 10-1)	[1 100 000–2 300 000]	[940 000–1 900 000]	[850 000–1 70	00 000]	
AWS AND POLICIES		STIGMA AND DI	SCRIMINATIC	N	
ws criminalizing the transmission of, non-					
sclosure of or exposure to HIV transmission	No	Percentage of women and	men aged 15-49	2006	201
		years who report discrimi	•		
iminalization of sex work		towards people living with	HIV	35.1	27.
	···				
		Percentage of people livin	g with HIV denied		
iminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	health services because of	_		
		the last 12 months			
	T				
rug use or possession for personal use is an	•	Percentage of people livin	a with HIV who		
fence	drug offences	reported a health-care pro	•		
	Neither criminalized nor	about their HIV status with			
iminalization of transgender people		about thom the otatao with	Tout thoir concorn		
	prosecuted				
ws or policies restricting the entry, stay and	No	VIOLENCE			
sidence of people living with HIV	INU	-VIOLLINCL			
rental consent for adelegants to access UN	/ Vas for adolescents vounger than				
arental consent for adolescents to access HIV	, ,	Proportion of ever-marrie		2006	201
sting	18 years	women aged 15-49 years			
pousal consent for married women to access		physical or sexual violence			
Jousal Consent for married women to access	N.I.	intimate partner in the pas	et 12 months	23	22
	No	intilitate partifer in the pas	ot 12 months		
xual and reproductive health services	No	mumate partner in the pas	it iz months	20	


EXPENDITURES						
		Fin	ancing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2014 ... US\$ 164 330 065 US\$ 164 330 065









Change in new HIV infections since 2010

Change in AIDS-related deaths since 2010

-56%

ratio

Incidence: prevalence 0.04


KEV	$P \cap P$	шлт	TONS
			10113

RETTOTOE THOTAS					
	Sex workers	Gay men and other men who have sex with men		Transgender people	Prisoners
Estimated size of population	657 829	238 175	127 532	25 984	185 182
HIV prevalence	1.6%	2.7%	6.3%	3.1%	
Know their HIV status	68.6%	69.2%	72%	59.7%	
Antiretroviral therapy coverage					
Condom use	90.8%	83.9%	77.4%	79.7%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	87 000 [56 000 –125 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	12.1%
Cervical cancer screening of women living with HIV (survey data) (2016)	35%
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



_				
0 — Pi	eople living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	- 0%
Allagos	79%	56%	46%	
All ages	[56->95%]	[40–79%]	[33–65%]	
Children (0, 44)	%	76%	%	
Children (0–14)	[%]	[53->95%]	[%]	
Manage (451)	87%	63%	%	
Women (15+)	[62->95%]	[45-88%]	[%]	
BB (451)	68%	50%	%	
Men (15+)	[48->95%]	[35–71%]	[–%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years (2016)

— Women	21.7%
— Men	31.5%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner) (2016)	
— Women	
— Men	40.8%
Women aged 15–49 years who have their	

demand for family planning satisfied by modern methods (2016)	72.8%
Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

Percentage of pregnant women living with HIV accessing antiretroviral medicines	0% [0–0%]	60% [41–89%]
Early infant diagnosis	6% [4–9%]	23% [16–33%]

Harm reduction

 Use of sterile injecting equipment at last injection (2015) 	86.4%
 Needles and syringes distributed per person who injects (2017) 	424.0
 Coverage of opioid substitution therapy (2017) 	19%
— Naloxone available (2016)	Yes
— Safe injection rooms available (2016)	No

INDONESIA

		2010	2017		
New HIV infections					
New HIV infections (all ages)	62 000 [54 000–70 000]	61 000 [54 000–70 000]	49 000 [43 000–57 000]	l	
New HIV infections (0–14)	1300 [1100–1500]	2700 [2200–3100]	3100 [2600–3800]		
New HIV infections (women, 15+)	18 000 [15 000–20 000]	22 000 [18 000–24 000]	17 000 [15 000–19 000]]	
New HIV infections (men, 15+)	43 000 [36 000–50 000]	37 000 [31 000–44 000]	29 000 [24 000–35 000]]	
HIV incidence per 1000 population	0.28 [0.24–0.31]	0.26 [0.22–0.29]	0.19 [0.16–0.22]]	
AIDS-related deaths					
AIDS-related deaths (all ages)	9000 [6600–12 000]	23 000 [19 000–29 000]	39 000 [33 000–45 000]]	
AIDS-related deaths (0–14)	680 [600–780]	1500 [1300–1800]	2200 [1800–2600]		
AIDS-related deaths (women, 15+)	1600 [1100–2200]	5300 [3900–6800]	12 000 [9800–14 000]		
AIDS-related deaths (men, 15+)	6700 [4700–8800]	16 000 [13 000–21 000]	25 000 [21 000–30 000]]	
eople living with HIV					
People living with HIV (all ages)	300 000 [260 000–340 000]	510 000 [440 000–590 000]			
People living with HIV (0–14)	2500 [2200–2900]	7100 [6200–8000]	14 000 [13 000–16 000]	1	
People living with HIV (women, 15+)	71 000 [63 000–79 000]	160 000 220 000 [140 000–180 000] [190 000–260 000]		00]	
People living with HIV (men, 15+)	220 000 [190 000–260 000]	350 000 [290 000–410 000]	390 000 [320 000–470 00	00]	
LAWS AND POLICIES		STIGMA AND DISCR	RIMINATION	1	
aws criminalizing the transmission of, non- lisclosure of or exposure to HIV transmission		Percentage of women and men	•	2007	2012
Criminalization of sex work		towards people living with HIV	,	57.1	62.8
Criminalization of same-sex sexual acts		Percentage of people living with health services because of their the last 12 months			
Orug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent			
Criminalization of transgender people					
Laws or policies restricting the entry, stay and residence of people living with HIV		VIOLENCE			
Parental consent for adolescents to access HI	V Yes, for adolescents younger than	Proportion of ever-married or p	artnered		

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES

Spousal consent for married women to access Yes

sexual and reproductive health services

Mandatory HIV testing for marriage, work or


residence permits or for certain groups


		Fin	ancing sources			
	Domestic private	Domestic public		International: Global Fund	International: all others	
Last available report: 2012		US\$ 36 851 913		US\$ 24 858 115	US\$ 55 100	US\$ 87 002 694


16 years


Yes

testing









Change in new HIV infections since 2010 = -19%

Change in AIDSrelated deaths = since 2010

Incidence: prevalence ratio

= 0.08


KEY POPULATIONS

RETTOTOE THOTAS					
	Sex workers	Gay men and other men who have sex with men		Transgender people	Prisoners
Estimated size of population	226 791	754 310	33 492	38 928	
HIV prevalence	5.3%	25.8%	28.76%	24.8%	1%
Know their HIV status					
Antiretroviral therapy coverage					0.3%
Condom use	67.8%	81.03%	46.3%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	45 000 [21 000 –78 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	27%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



Allower	42%	14%	%	
All ages	[36–49%]	[12–17%]	[%]	
Children (0-14)	%	25%	%	
Ciliaren (0–14)	[%]	[22–28%]	[%]	
Momon (4E+)	%	14%	%	
Women (15+)	[%]	[12–17%]	[%]	
Men (15+)	%	14%	%	
	[%]	[12–17%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15–24 years

— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2012)	79%

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	3%	13%
accessing antiretroviral medicines	[2–3%]	[11–15%]
Early infant diagnasis	%	1%
Early infant diagnosis	[_ %]	[1_1%]

Harm reduction

 Use of sterile injecting equipment at last injection (2015) 	88.85%
 Needles and syringes distributed per person who injects (2017) 	3.01
 Coverage of opioid substitution therapy (2017) 	12%
— Naloxone available (2016)	
— Safe injection rooms available (2016)	

JAPAN

		2010	2017	
New HIV infections				
New HIV infections (all ages)	1400	1500	1500	
	[1000–1600]	[1100–1800]	[1100–1700]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	<200	<200	<100	
	[<200– <200]	[<100- <200]	[<100– <100]	
New HIV infections (men, 15+)	1200	1400	1400	
	[860–1400]	[990–1700]	[1000–1700]	
HIV incidence per 1000 population	0.01 [<0.01–0.01]	0.01 [<0.01–0.01]	0.01 [<0.01–0.01]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<200	<200	<200	
	[<100- <500]	[<100- <200]	[<100- <200]	
AIDS-related deaths (0-14)				
	[–]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100- <100]	[<100- <100]	[<100- <100]	
AIDS-related deaths (men, 15+)	<200	<100	<100	
	[<100- <200]	[<100- <200]	[<100– <200]	
People living with HIV				
People living with HIV (all ages)	12 000	19 000	28 000	
	[9800–14 000]	[16 000–22 000]	[24 000–32 000]	
People living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	1600	2200	2600	
	[1400–1800]	[2000–2500]	[2300–2900]	
People living with HIV (men, 15+)	10 000	16 000	25 000	
	[8300–12 000]	[13 000–19 000]	[21 000–29 000]	
LAWS AND POLICIES		STIGMA AND [DISCRIMINATION	
Laws criminalizing the transmission of, n disclosure of or exposure to HIV transmis		Percentage of women a		
Criminalization of sex work		years who report discriminatory attitudes towards people living with HIV		
Criminalization of same-sex sexual acts			Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use offence	is an	Percentage of people li	ving with HIV who	

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

reported a health-care professional told others about their HIV status without their consent

sexual and reproductive health services

Mandatory HIV testing for marriage, work or residence permits or for certain groups

Criminalization of transgender people

residence of people living with HIV

Laws or policies restricting the entry, stay and


Parental consent for adolescents to access HIV


Spousal consent for married women to access


EXPENDITURES						
		Fin	ancing sources			
	Domestic private	Domestic public		International: Global Fund	International: all others	Total


Last available report: 2011 ... US\$ 67 907 854 US\$ 67 907 854

testing









Change in new -1% HIV infections since 2010

Change in AIDS-related deaths since 2010

Incidence: ratio

prevalence 0.05


KEY POPULATIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	0%	4.8%	0.02%		
Know their HIV status					
Antiretroviral therapy coverage					
Condom use		71%	40%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	89 [73–110]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed	
All ages	%	82%	%	
All ages	[%]	[70–95%]	[%]	
Children (0-14)	%	%	%	
Cilidren (0–14)	[%]	[%]	[%]	
Women (15+)	%	85%	%	
Wollieff (15+)	[%]	[75->95%]	[%]	
Mon (45+)	%	82%	%	
Men (15+)	[%]	[69->95%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years

— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by	

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Early infant diagnosis	%	%

Harm reduction

modern methods

 Use of sterile injecting equipment at last injection (2014) 	17.1%
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	
— Safe injection rooms available (2016)	

LAO PEOPLE'S DEMOCRATIC REPUBLIC

EPIDEMIC ESTIMATES			
	2005	2010	2017
New HIV infections			
New HIV intections (all ages)	 [–]	 []	 []
New HIV intections (0–14)	 [–]	 []	 [-]
New HIV intections (women, 15+)	 []	 []	 [=]
New HIV infections (men. 15+)	 []	 []	 []
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500 [<200– <500]	<500 [<500– <500]	<500 [<500–<500]
AIDS-related deaths (0–14)	<100 [<100– <100]	<100 [<100-<100]	<100 [<100-<100]
AIDS-related deaths (women, 15+)	<100 [<100– <100]	<200 [<100- <200]	<200 [<100-<200]
AIDS-related deaths (men. 15+)	<100 [<100– <200]	<200 [<200– <500]	<200 [<200– <500]
People living with HIV			
eople living with HIV (all ages)	6800 [6100–7600]	10 000 [9000–12 000]	12 000 [10 000–14 000]
People living with HIV (0–14)	<500 [<500– <500]	<500 [<500–570]	670 [590–790]
People living with HIV (women 15+)	2800 [2500–3100]	4200 [3800–4900]	5100 [4500–5800]
People living with HIV (men. 15+)	3800 [3400–4200]	5400 [4800–6200]	6100 [5300–7200]
LAWS AND POLICIES		STIGMA AND DISCF	RIMINATION
aws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and mer	_
Criminalization of sex work	Selling sexual services is criminalized	years who report discriminator towards people living with HIV	
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Orug use or possession for personal use is an offence	There is compulsory detention for drug offences	Percentage of people living wit	
Criminalization of transgender people	Neither criminalized nor prosecuted	reported a health-care professional told others about their HIV status without their consent	
aws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV esting	Yes, for adolescents younger than 14 years	Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months	
Spousal consent for married women to access sexual and reproductive health services	No		
Mandatory HIV testing for marriage, work or	Yes		

EXPENDITURES						
Financing sources						
				International: Global Fund	International: all others	

US\$ 459 782


US\$ 3 246 284


US\$ 4 633 491


US\$ 569 221


residence permits or for certain groups

Last available report: 2017









Change in new HIV infections since 2010

Change in AIDSrelated deaths since 2010

10%

Incidence: prevalence ratio

= ..

treatment

$K \vdash V$	P() P		
	1 () [\cup	FIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	13 400	50 000	1 600		
HIV prevalence		1.6%			
Know their HIV status		10.2%			
Antiretroviral therapy coverage					
Condom use	91.8%	25.7%			
Coverage of HIV prevention programmes	50.7%	7.8%		50.7%	
Avoidance of health care because of stigma and discrimination	2.3%	41.8%			

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	710 [450–1000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	13%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined	

Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment

Knowledge of HIV prevention among young

Condom use at last higher-risk sex (with a

Women aged 15–49 years who have their demand for family planning satisfied by

Men aged 15-49 years who are circumcised

Male circumcisions performed according to

non-marital, non-cohabiting partner)

HIV PREVENTION

people aged 15-24 years

— Women

— Women

— Men


modern methods

national standards

Harm reduction

— Men

HIV TESTING AND TREATMENT CASCADE



0 —				0%
-	pple living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	0 76
Allone	75%	47%	45%	
All ages	[66–87%]	[42–55%]	[39–52%]	
01:11.1(0.44)	%	41%	35%	
Children (0–14)	[%]	[36-48%]	[30-40%]	
Women (15+)	%	50%	47%	
	[%]	[44–57%]	[42–54%]	
Man (451)	%	46%	44%	
Men (15+)	[%]	[40-55%]	[38–51%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

People who received PrEP at least once during the reporting period (2017)

 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects (2017) 	2.5
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

Percentage of pregnant women living with HIV accessing antiretroviral medicines	7% [6–8%]	24% [20–28%]
Early infant diagnosis	1% [1–1%]	7% [6–8%]

...

Not

applicable

Not

applicable

MALAYSIA

	2005	2010	2017
New HIV infections			
New HIV infections (all ages)	8100	7200	7800
(an ages)	[7300–8800]	[6500–7800]	[7000–8500]
New HIV infections (0-14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
New HIV infections (women, 15+)	1300	1400	1100
	[1100–1500]	[1200–1600]	[960–1200]
New HIV infections (men, 15+)	6700	5800	6700
	[6000–7300]	[5200–6300]	[6000–7300]
HIV incidence per 1000 population	0.32 [0.29–0.34]	0.26 [0.23–0.28]	0.25 [0.22–0.27]
AIDS-related deaths			
AIDS-related deaths (all ages)	5100	5400	4400
	[4400–5800]	[4600–6000]	[3700–5200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	800	900	780
	[640–930]	[730–1000]	[620–950]
AIDS-related deaths (men, 15+)	4300	4500	3600
	[3700–4800]	[3900–5000]	[3000–4200]
eople living with HIV			
People living with HIV (all ages)	75 000	80 000	87 000
(3.1)	[65 000–88 000]	[70 000–94 000]	[76 000–99 000]
People living with HIV (0–14)	570	580	<500
	[<500–660]	[<500–670]	[<500-<500]
People living with HIV (women, 15+)	12 000 [11 000–14 000]	15 000 [13 000–18 000]	17 000 [15 000–19 000]
	62 000	65 000	70 000
People living with HIV (men, 15+)	[54 000–73 000]	[56 000–76 000]	[61 000–80 000]
	[34 000-73 000]	[30 000-70 000]	[01 000-00 000]
LAWS AND POLICIES		STIGMA AND I	DISCRIMINATION
aws criminalizing the transmission of, ne	on-		
isclosure of or exposure to HIV transmis	ssion	Percentage of women a	
Criminalization of sex work	Selling and buying sexual services	years who report discriminatory attitudes towards people living with HIV	

Criminalization of sex work

Selling and buying sexual services is criminalized

Criminalization of same-sex sexual acts

...

Drug use or possession for personal use is an offence

There is compulsory detention for drug offences

Criminalization of transgender people

Both criminalized and prosecuted

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

Percentage of people living with HIV denied

health services because of their HIV status in

Laws or policies restricting the entry, stay and residence of people living with HIV

Parental consent for adolescents to access HIV Yes, for adolescents younger than testing 18 years

Spousal consent for married women to access No

sexual and reproductive health services

Mandatory HIV testing for marriage, work or residence permits or for certain groups

Yes

VIOLENCE


the last 12 months


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


	Fina	ancing sources		

Last available report: 2017 US\$ 721 955 US\$ 35 065 813 ... US\$ 906 297 ... US\$ 36 935 753









Change in new HIV infections since 2010

9%

Change in AIDSrelated deaths since 2010 Incidence: prevalence ratio

-18%

= 0.09


		TIOI	

KETT OF CEATIONS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	21 000	140 000	120 000	24 000	
HIV prevalence	6.3%	21.6%	13.5%	10.9%	0.11%
Know their HIV status	35.1%	43.3%	38.9%	43%	
Antiretroviral therapy coverage	22.5%	62.6%	34.6%	34%	
Condom use	83.5%	65.4%	25.7%	78.2%	
Coverage of HIV prevention programmes	40%	36.7%	1.4%	40%	
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	1700 [1400 –2000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	5.7%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



0				0 70
	People living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	
Allogoo	83%	45%	42%	
All ages	[73–95%]	[39–51%]	[37–48%]	
Children (0-1	95%	95%	89%	
Cilidren (0-	[83->95%]	[83->95%]	[78->95%]	
Woman (15+)	65%	60%	55%	
Women (15+)	[57–73%]	[53–68%]	[48–62%]	
Men (15+)	87%	41%	39%	
Well (15+)	[77->95%]	[36–47%]	[34–45%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	65% [55–76%]	>95% [87- >95%]
Early infant diagnosis	61% [52–72%]	>95% [86– >95%]

HIV PREVENTION

— Women

— Men

Knowledge of HIV prevention among young people aged 15–24 years (2015)

— Men	41.8%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

Harm reduction

 Use of sterile injecting equipment at last injection (2017) 	79.5%
 Needles and syringes distributed per person who injects (2017) 	13.67
 Coverage of opioid substitution therapy (2017) 	83%
— Naloxone available (2016)	Yes
— Safe injection rooms available (2016)	No

41.1%

MONGOLIA

EPIDEMIC ESTIMATES					
	2005	2010	2017		
lew HIV infections					
New HIV infections (all ages)	<100 [<100–<100]	<100 [<100- <100]	<100 [<100-<100]		
New HIV infections (0–14)	 []	 []	 []		
New HIV infections (women, 15+)	<100 [<100– <100]	<100 [<100- <100]	<100 [<100- <100]		
New HIV infections (men, 15+)	<100 [<100– <100]	<100 [<100- <100]	<100 [<100-<100]		
HIV incidence per 1000 population	0.01 [<0.01–0.01]	0.03 [0.02–0.04]	0.01 [<0.01–0.	02]	
AIDS-related deaths					
AIDS-related deaths (all ages)	<100 [<100–<100]	<100 [<100- <100]	<100 [<100-<100]		
AIDS-related deaths (0–14)	[]	 []	 [–]		
AIDS-related deaths (women, 15+)	<100 [<100– <100]	<100 [<100-<100]	<100 [<100–<100]		
AIDS-related deaths (men, 15+)	<100 [<100– <100]	<100 [<100- <100]	<100 [<100- <100]		
eople living with HIV					
People living with HIV (all ages)	<100 [<100– <100]	<500 [<500– <500]	650 [540–750]		
People living with HIV (0–14)	[]	 []	 []		
People living with HIV (women, 15+)	<100 [<100- <100]	<100 [<100-<100]	<200 [<200–<200]		
People living with HIV (men, 15+)	<100 [<100– <100]	<500 [<500– <500]	<500 [<500–590]		
LAWS AND POLICIES		STIGMA AND D	ISCRIMINATIO	N	
aws criminalizing the transmission of, non- lisclosure of or exposure to HIV transmission	ı	Percentage of women an	•	2005	2014
Criminalization of sex work			towards people living with HIV 67.9*		72.7
Criminalization of same-sex sexual acts		Percentage of people liv health services because the last 12 months	•		
Drug use or possession for personal use is a ffence	n	Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent			
Criminalization of transgender people					
Laws or policies restricting the entry, stay and	d	VIOLENCE			

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

*Female respondents only

EXPENDITURES

Parental consent for adolescents to access HIV Yes, for adolescents younger than

Spousal consent for married women to access No

sexual and reproductive health services

Mandatory HIV testing for marriage, work or

residence permits or for certain groups


18 years


Yes


	Fina	ancing sources			
Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2014 US\$ 72 379 US\$ 1 619 212 US\$ 2 858 199

testing









Change in new HIV infections = -60% since 2010

Change in AIDSrelated deaths since 2010

260% Incidence: prevalence ratio

prevalence = 0.05


KEY POPULATIONS

KETTOTOE (HOTS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	1 293	3 118			•••
HIV prevalence	0%	9.2%			
Know their HIV status	76.4%	87.7%			
Antiretroviral therapy coverage					
Condom use	84.3%	78.5%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	12 [9–16]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	12%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment (2017)	100%
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2017)	0%

HIV TESTING AND TREATMENT CASCADE



₩ 100				
0 — Peopl	e living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	- 0%
All ages	32% [27–38%]	28% [23–33%]	% [–%]	
Children (0-14)	% [–%]	% [–%]	% [–%]	
Women (15+)	28% [23–33%]	22% [19–26%]	22% [19–26%]	
Men (15+)	34% [28–40%]	30% [25–36%]	28% [24–33%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

— Women

Knowledge of HIV prevention among young people aged 15–24 years (2014)

— Men	20.7%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2013)	77.3%
Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to	Not

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Early infant diagnosis	% [_ %]	%

Harm reduction

national standards

People who received PrEP at least once during the reporting period (2017)

 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	
— Safe injection rooms available (2016)	


22.8%


applicable


MYANMAR


	2005	2010	2017	
	2005	2010	2017	
ew HIV infections	00.000	45.000	44.000	
ew HIV infections (all ages)	23 000	15 000	11 000	
	[21 000–25 000]	[14 000–17 000]	[9900–12 000]	
ew HIV infections (0-14)	1400	1100	750	
	[1200–1700]	[770–1500]	[630–900]	
ew HIV infections (women, 15+)	7500	5300	3000	
	[6600–8400]	[4600–5900]	[2700–3400]	
ew HIV infections (men, 15+)	14 000	9100	7100	
	[12 000–15 000]	[8100–9900]	[6400–7800]	
IV incidence per 1000 population	0.48 [0.43–0.52]	0.31 [0.28–0.34]	0.21 [0.19–0.23]	
DS-related deaths				
DS related deaths (all ages)	13 000	13 000	6700	
DS-related deaths (all ages)	[11 000–15 000]	[11 000–15 000]	[5100–9300]	
DS related deaths (0, 44)	780	630	<500	
DS-related deaths (0–14)	[670–920]	[<500–900]	[<500-<500]	
DO related deaths (3000	3500	1400	
DS-related deaths (women, 15+)	[2400–3700]	[2800-4100]	[1000–2100]	
	9200	9000	5100	
DS-related deaths (men, 15+)	[7800–11 000]	[7700–10 000]	[3900–6900]	
ople living with HIV			<u> </u>	
	210 000	210 000	220 000	
People living with HIV (all ages)	[180 000–240 000]	[180 000–250 000]	[200 000–260 000]	
	5100	7100	8400	
eople living with HIV (0–14)	[4400–5900]	[6000–8500]	[7200–10 000]	
	58 000	67 000	79 000	
eople living with HIV (women, 15+)	[51 000–66 000]	[58 000–78 000]	[70 000–90 000]	
	150 000	140 000	140 000	
eople living with HIV (men, 15+)	[130 000–170 000]	[120 000–170 000]	[120 000–160 000]	
	[130 000-170 000]	[120 000-170 000]	[120 000-100 000]	
AWS AND POLICIES		STIGMA AND D	ISCRIMINATION	
		STIGINA AND D	13CKIIVIII VATION	
ws criminalizing the transmission of, non-	No	B		201
sclosure of or exposure to HIV transmission		Percentage of women ar years who report discrin		
	Selling sexual services is	towards people living wi		
riminalization of sex work	criminalized	towards people living wi		63.
A CARLO DE CARLO CARLO COMO DE CARLO D		Percentage of people liv		
riminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)			
		the last 12 months		
rug use or possession for personal use is an	Possession of drugs for personal			
fence	use is specified as a non-criminal	Percentage of people liv	ing with HIV who	
	offence	reported a health-care p	•	
	Neither criminalized nor	about their HIV status w		
iminalization of transgender people	prosecuted			
ws or policies restricting the entry, stay and	<u>'</u>			
we or noliciae restricting the entry stay and	No	VIOLENCE		
sidence of people living with HIV		Burnett and the second second		201
sidence of people living with HIV	V No	Droportion of over marri	Proportion of ever-married or partnered	
sidence of people living with HIV rental consent for adolescents to access HI	V No			
sidence of people living with HIV rental consent for adolescents to access HIV sting	No	women aged 15-49 year	s who experienced	
sidence of people living with HIV rental consent for adolescents to access HIV sting oousal consent for married women to access	No	women aged 15–49 year physical or sexual violer	s who experienced nce from a male	11
sidence of people living with HIV rental consent for adolescents to access HIV sting ousal consent for married women to access	NO .	women aged 15-49 year	s who experienced nce from a male	11
sidence of people living with HIV rental consent for adolescents to access HIV sting	NO .	women aged 15–49 year physical or sexual violer	s who experienced nce from a male	11

EXPENDITURES						
		Fin	ancing sources			
Last available report: 2013	US\$ 4 307 590	US\$ 4 131 753	US\$ 1 072 833	US\$ 26 854 010	US\$ 18 047 417	US\$ 56 389 652









Change in new HIV infections since 2010 = -29%

Change in AIDSrelated deaths since 2010 Incidence: prevalence ratio

prevalence = 0.05


KEY POPULATIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	66 000	252 000	93 000		
HIV prevalence	5.4%	6.4%	34.9%		5.6%
Know their HIV status	44.6%	52.4%	27.9%		
Antiretroviral therapy coverage			14.1%		
Condom use	81.1%	77.1%	21.9%		
Coverage of HIV prevention programmes			34.2%		
Avoidance of health care because of stigma and discrimination			4.4%		

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	18 000 [13 000 –24 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	11.4%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment (2017)	74.4%
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



All ages	%	66% [58–77%]	%	
	[%]	[38-77%]	[%]	
Children (0-14)	%	91%	%	
Children (0-14)	[%]	[77->95%]	[%]	
Women (15+)	%	80%	%	
	[%]	[70–91%]	[%]	
Men (15+)	%	56%	%	
	[%]	[49–66%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15–24 years (2016)

— Women	16.2%
— Men	17.8%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	74.9%
Men aged 15–49 years who are circumcised (2016)	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	52%	78%
accessing antiretroviral medicines	[43–62%]	[67–90%]
Early infant diagnosis	1%	28%
Early Illiant diagnosis	[1–2%]	[25-33%]

Harm reduction

 Use of sterile injecting equipment at last injection (2017) 	90.8%
 Needles and syringes distributed per person who injects (2017) 	358.47
 Coverage of opioid substitution therapy (2017) 	15%
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No

NEPAL

EPIDEMIC ESTIMATES					
	2005	2010	2017		
New HIV infections					
New HIV infections (all ages)	3900	2100	840		
New Filv Illiections (all ages)	[3500–4300]	[1900–2300]	[750–910]		
New HIV infections (0–14)	<500	<200	<100		
, ,	[<500-<500]	[<200–<500]	[<100-<100]		
New HIV infections (women, 15+)	1100 [980–1300]	620 [530–690]	<500 [<500– <500]		
	2500	1300	520		
New HIV infections (men, 15+)	[2300–2800]	[1200–1400]	[<500–580]		
LIN/ in all damage and 4000 are modeling	· · · · · · · · · · · · · · · · · · ·		<u> </u>		
HIV incidence per 1000 population	0.16 [0.14–0.17]	0.08 [0.07–0.09]	0.03 [0.03–0.03]		
AIDS-related deaths					
AIDS-related deaths (all ages)	1500	1700	1300		
	[1200–1800] <200	[1400–1900] <200	[1000–1700] <100		
AIDS-related deaths (0–14)	[<200-<200]	[<100-<200]	[<100-<100]		
	<500	<500	<500		
AIDS-related deaths (women, 15+)	[<500- <500]	[<500-<500]	[<200–<500]		
	950	1200	1000		
AIDS-related deaths (men, 15+)	[740–1200]	[980–1300]	[800–1200]		
People living with HIV					
	33 000	34 000	31 000		
People living with HIV (all ages)	[29 000–37 000]	[30 000–41 000]	[27 000–36 000]		
People living with HIV (0–14)	940	1300	1200		
r copie iiving with this (0-14)	[810–1100]	[1100–1500]	[1000–1400]		
People living with HIV (women, 15+)	9900	11 000	11 000		
, , , , , , , , , , , , , , , , , , , ,	[8700–11 000]	[9700–13 000]	[10 000–13 000]		
People living with HIV (men, 15+)	22 000	22 000	18 000		
	[19 000–25 000]	[19 000–26 000]	[16 000–22 000]		
LAWS AND POLICIES		STIGMA AND DISCR	IMINATION		
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men	aged 15-49	2006	2016
uisclosure of or exposure to fire transmission		years who report discriminatory attitudes			
Criminalization of sex work	Selling and buying sexual services			26.5	32.5
orminalization of cox work	is criminalized			20.0	02.0
		Percentage of people living with HIV denied health services because of their HIV status in			
Criminalization of same-sex sexual acts	No penalty specified				
		the last 12 months			
Drug upo or possession for nevertal versity	Possession of drugs for personal				
Drug use or possession for personal use is an offence	use is specified as a criminal	Percentage of people living with	n HIV who		
	offence	reported a health-care profession			
Criminalization of transporter nos-!-	Neither criminalized nor	about their HIV status without the			
Criminalization of transgender people	prosecuted				
Laws or policies restricting the entry, stay and		VIOLENICE			
residence of people living with HIV	No	VIOLENCE			

sexual and reproductive health services	INO
Mandatory HIV testing for marriage, work or	No

Spousal consent for married women to access No

residence permits or for certain groups

Parental consent for adolescents to access HIV Yes, for adolescents younger than

16 years

Proportion of ever-married or partnered women aged 15–49 years who experienced	2011
physical or sexual violence from a male	
intimate partner in the past 12 months	14.3


2016


11.2


EXPENDITURES


	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	
Financing sources							

testing









Change in new -61% HIV infections since 2010

related deaths since 2010

Incidence: prevalence ratio

-23%

0.03


KEY POPULATIONS

RETTOTOL (TIONS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	67 300	60 333	30 868	21 460	
HIV prevalence		5%	8.8%	8.5%	
Know their HIV status		89.6%	54%	89.4%	
Antiretroviral therapy coverage					
Condom use		94.6%	48.9%	91.5%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	950 [520–1500]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	27.3%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and	

HIV TESTING AND TREATMENT CASCADE



Реор	le living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	-
All agos	64%	49%	44%	
All ages	[56–74%]	[43–58%]	[39–52%]	
Children (0-14)	83%	>95%	60%	
	[71->95%]	[94->95%]	[52–71%]	
Manage (451)	63%	60%	57%	
Women (15+)	[56–74%]	[53–70%]	[50-66%]	
Men (15+)	62%	39%	36%	
	[54–74%]	[33-46%]	[31–43%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

Yes

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	13%	63%
accessing antiretroviral medicines	[11–16%]	[53–75%]
Early infant diagnosis	3%	45%
Early Illiant diagnosis	[3-4%]	[38-53%]

HIV PREVENTION

treatment

hepatitis C virus starting hepatitis C

Knowledge of HIV prevention among young people aged 15-24 years (2016)

— Women	20.7%
— Men	27.1%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner) (2016)	
— Women	
— Men	67.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	56.3%
Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once	

Harm reduction

during the reporting period (2017)

 Use of sterile injecting equipment at last injection (2017) 	97.6%
 Needles and syringes distributed per person who injects (2017) 	60.64
 Coverage of opioid substitution therapy (2017) 	3%
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No

...

NEW ZEALAND

EDIDEMIC ECTIMATES			
EPIDEMIC ESTIMATES			
	2005	2010	2017
New HIV infections			
New HIV infections (all ages)			
	[–]	[=]	[]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)			
	[]	[]	[]
New HIV infections (men, 15+)			
	[]	[]	[–]
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <200]	[<100- <200]	[<100- <100]
AIDS-related deaths (0-14)			
	[]	[]	[–]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100– <100]	[<100–<100]	[<100- <100]
People living with HIV			
People living with HIV (all ages)	2000	2300	3700
	[<100–9800]	[<100–9900]	[<200–13 000]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	<500	530	820
	[<100–2300]	[<100–2600]	[<100–3200]
People living with HIV (men, 15+)	1500	1800	2900
	[<100–7400]	[<100–7400]	[<100–9300]
LAWS AND POLICIES		STIGMA AND	DISCRIMINATION
Laws criminalizing the transmission of, n disclosure of or exposure to HIV transmis		t based Percentage of women years who report disc	•

Sex work is not subject to punitive Criminalization of sex work regulations or is not criminalized Laws penalizing same-sex sexual Criminalization of same-sex sexual acts acts have been decriminalized or never existed Drug use or possession for personal use is an Drug use or consumption is a offence specific offence in law Neither criminalized nor Criminalization of transgender people prosecuted Laws or policies restricting the entry, stay and residence of people living with HIV Parental consent for adolescents to access HIV No testing Spousal consent for married women to access No sexual and reproductive health services Mandatory HIV testing for marriage, work or Yes residence permits or for certain groups

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


Financing sources							

Last available report: 2017 US\$ 30 068 244









Change in new HIV infections since 2010

Change in AIDS-related deaths since 2010

-24%

Incidence: prevalence ratio


KEY POPULATIONS

RETTOTOL (TIONS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence		6.5%			
Know their HIV status					
Antiretroviral therapy coverage					
Condom use		81%	34%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	0 [0–0]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



All ages	%	78%	%	
rai agoo	[%]	[3->95%]	[%]	
Obildes (0, 44)	%	%	%	
Children (0-14)	[%]	[%]	[%]	
	%	77%	%	
Women (15+)	[%]	[2->95%]	[%]	
BE (4 E .)	%	78%	%	
Men (15+)	[%]	[3->95%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

— Women

Knowledge of HIV prevention among young people aged 15-24 years

demand for family planning satisfied by

— Men	•••
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their	

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

Harm reduction


modern methods


 Use of sterile injecting equipment at last injection (2016) 	62.1%
 Needles and syringes distributed per person who injects (2016) 	277.0
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No


PAKISTAN


	2005	2010	2017	
New HIV infections				
	9400	14 000	20 000	
New HIV infections (all ages)	[8400–10 000]	[12 000–15 000]	[18 000–21 000]	
	<100	510	950	
lew HIV infections (0–14)	[<100- <200]	[<500–600]	[800–1100]	
	2600	3800	5400	
lew HIV infections (women, 15+)	[2300–3000]	[3200–4200]	[4700–6000]	
	6700	9400	13 000	
lew HIV infections (men. 15+)	[6000–7300]	[8400–10 000]	[12 000–15 000]	
	-			
IV incidence per 1000 population	0.06 [0.06–0.07]	0.08 [0.07–0.09]	0.1 [0.09–0.11]	
IDS-related deaths				
IDS-related deaths (all ages)	<100	1300	6200	
ibo-related deaths (all ages)	[<100- <100]	[840–1800]	[5000–7300]	
IDC related deaths (0, 44)	<100	<500	530	
IDS-related deaths (0–14)	[<100-<100]	[<200-<500]	[<500–630]	
IDO ALLA CALLA CAL	<100	<500	1700	
IDS-related deaths (women, 15+)	[<100- <100]	[<200-<500]	[1400–2100]	
	<100	780	3900	
AIDS-related deaths (men. 15+)	[<100 [<100–<100]	[<500–1100]	[3200–4700]	
	100 100	[1000 1100]	[0200 1700]	
eople living with HIV	12.000	// 000	150,000	
eople living with HIV (all ages)	12 000	66 000	150 000	
	[11 000–13 000]	[59 000–73 000]	[130 000–170 000]	
eople living with HIV (0–14)	<200	1100	3500	
	[<100– <200]	[920–1200]	[3000–4000]	
eople living with HIV (women, 15+)	3400	19 000	43 000	
(,,	[3000–3700]	[17 000–21 000]	[38 000–49 000]	
People living with HIV (men, 15+)	3400	46 000	99 000	
oopio iiviig viiii iiv (iiioii, 10-7)	7500–9200]	[41 000–50 000]	[87 000–110 000]	
AWS AND POLICIES		STIGMA AND [DISCRIMINATION	
aws criminalizing the transmission of, non-				
isclosure of or exposure to HIV transmission	No	Percentage of women a	and men aged 15–49	201
		years who report discri	minatory attitudes	
Criminalization of sex work	Selling and buying sexual services	towards people living v	vith HIV	49
illillialization of Sex work	is criminalized			47
		Percentage of people li	ving with HIV denied	
Criminalization of same-sex sexual acts	Yes, death penalty	health services becaus	_	
Timmunization of dame dox doxual dots	res, death penalty	the last 12 months		
Orug use or possession for personal use is an	Drug use or consumption is a			
ffence	specific offence in law	Percentage of people li		
		the state of the s	professional told others	
Criminalization of transgender people	Neither criminalized nor	about their HIV status v	vithout their consent	
	prosecuted			
aws or policies restricting the entry, stay and		VIOLENCE		
esidence of people living with HIV	No	VIOLENCE		
	Yes, for adolescents younger than	Proportion of ever-mar	ried or partnered	201
arental consent for adolescents to access HIV	18 years	women aged 15–49 year		201
esting		physical or sexual viole	ence from a male	
esting pousal consent for married women to access	Yes	physical or sexual viole intimate partner in the		18
esting pousal consent for married women to access	•			18
Parental consent for adolescents to access HIV testing Spousal consent for married women to access sexual and reproductive health services Mandatory HIV testing for marriage, work or	•			

EXPENDITURES					
	Fin	ancing sources			
Last available report: 2013	115\$ 2 421 948		IIS\$ 5 311 225	115\$ 330 927	115¢ 9 993 630









Change in new HIV infections 45% since 2010

related deaths since 2010

Incidence: ratio

prevalence 0.14


KEY POPULATIONS

ICET TOTOLATIONS					
	Sex workers	Gay men and other men who have sex with men		Transgender people	Prisoners
Estimated size of population	228 787	832 213	113 422	52 646	77 500
HIV prevalence	3.8%	3.7%	21%	5.5%	
Know their HIV status	30.6%	22.3%	39.3%	29%	
Antiretroviral therapy coverage	4.3%	0.1%	10.3%	3.2%	
Condom use	35.1%	22.4%	15.3%	24.4%	
Coverage of HIV prevention programmes	0.7%	1.2%	1.6%	0.7%	
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	6900 [3200 –12 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C	

HIV TESTING AND TREATMENT CASCADE



ag 40 000 20 000	108912	second 106075		0: 25%
0 ————————————————————————————————————	living with HIV who know	People living with HIV on	People living with HIV who are	- 0%
Георге	their status	treatment	virally suppressed	
All ages	15%	8%	8%	
All ages	[13–17%]	[7–9%]	[7–9%]	
Children (0-14)	20%	13%	13%	
Cilitaren (0-14)	[18–24%]	[11–15%]	[11–15%]	
Women (15+)	14%	6%	%	
Women (15+)	[12–16%]	[5–6%]	[%]	
Man (451)	16%	9%	9%	
Men (15+)	[14-18%]	[8-11%]	[8–10%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

treatment

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years

people agea 10-24 years	
— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2013)

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	1%	6%
accessing antiretroviral medicines	[1–2%]	[5–7%]
Early infant diagnosis	1%	1%
Early infant diagnosis	[1_2%]	[1_1%]

Harm reduction

— Men

 Use of sterile injecting equipment at last injection (2016) 	72.5%
 Needles and syringes distributed per person who injects (2017) 	241.92
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No

47%

PAPUA NEW GUINEA

EPIDEMIC ESTIMATES			
	2005	2010	2017
New HIV infections			
New HIV infections (all ages)	3200 [2700–3800]	2800 [2500–3200]	3000 [2500–3600]
New HIV infections (0-14)	530 [<500–630]	530 [<500–630]	<500 [<500–530]
New HIV infections (women, 15+)	1500 [1200–1800]	1300 [1100–1500]	1400 [1200–1800]
New HIV infections (men, 15+)	1200 [940–1400]	1000 [830–1200]	1100 [900–1400]
HIV incidence per 1000 population	0.52 [0.44–0.62]	0.41 [0.36–0.46]	0.37 [0.31–0.45]
AIDS-related deaths			
AIDS-related deaths (all ages)	1800 [1400–2400]	1600 [1200–1900]	1100 [860–1400]
AIDS-related deaths (0-14)	<500 [<500- <500]	<500 [<500- <500]	<500 [<200- <500]
AIDS-related deaths (women, 15+)	830 [610–1100]	690 [530–850]	<500 [<500–560]
AIDS-related deaths (men, 15+)	710 [530–990]	560 [<500–720]	<500 [<500–560]
People living with HIV			
People living with HIV (all ages)	33 000 [29 000–37 000]	38 000 [34 000–42 000]	48 000 [43 000–52 000]
People living with HIV (0–14)	2100 [1700–2500]	3000 [2400–3400]	3400 [2600–3900]
People living with HIV (women, 15+)	17 000 [15 000–19 000]	20 000 [18 000–22 000]	26 000 [23 000–28 000]
People living with HIV (men, 15+)	14 000 [12 000–16 000]	15 000 [14 000–17 000]	19 000 [16 000–21 000]
LAWS AND POLICIES		STIGMA AND I	DISCRIMINATION
Laws criminalizing the transmission of, nodicious control of the c	Voc	Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Criminalization of sex work	Selling sexual services is criminalized		
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)	Percentage of people li health services becaus the last 12 months	
Drug use or possession for personal use offence	is an Drug use or consumption is a specific offence in law	Percentage of people li	
		reported a health-care professional told others	

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

about their HIV status without their consent

EXPENDITURES

Criminalization of transgender people

residence of people living with HIV

sexual and reproductive health services

Mandatory HIV testing for marriage, work or

residence permits or for certain groups

Laws or policies restricting the entry, stay and

Spousal consent for married women to access No

	Fin	ancing sources		
Domostic private	Domostic public	International: PEPFAR		Total
		international. FLFI AR		

Neither criminalized nor

prosecuted


14 years


Yes


Parental consent for adolescents to access HIV Yes, for adolescents younger than


Last available report: 2012 US\$ 740 081 US\$ 6 385 677 ... US\$ 1 577 356 US\$ 2 048 635 US\$ 36 659 267

testing









Change in new HIV infections since 2010

5%

related deaths since 2010

-28% ratio

Incidence: prevalence

0.06


KEY POPULATIONS

Estimated size of population			 	
HIV prevalence			 	
Know their HIV status	56.9%	59%	 	
Antiretroviral therapy coverage			 	
Condom use		63.1%	 	
Coverage of HIV prevention programmes			 	
Avoidance of health care because of stigma and discrimination			 	

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	3600 [2000 –5500]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	9.2%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



%	55%	%	
[%]	[50-61%]	[%]	
%	40%	%	
[%]	[31–45%]	[%]	
%	59%	%	
[%]	[53–65%]	[%]	
%	53%	%	
[%]	[46–60%]	[%]	
	[%]% [%]% [%]	[%] [50–61%]% 40% [%] [31–45%]% 59% [%] [53–65%]% 53%	[%] [50–61%] [%]% 40%% [%] [31–45%] [%]% 59%% [%] [53–65%] [%]% 53%%

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years

— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	5%	41%
accessing antiretroviral medicines	[4–5%]	[32–47%]
Early infant diagnosis	%	35%
Early Illiant diagnosis	[_ %]	[30_45%]

Harm reduction


 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No


COUNTRY DATA


PHILIPPINES


EPIDEMIC ESTIMATES					
	2005	2010	2017		
New HIV infections					
New HIV infections (all ages)	980 [870–1000]	4400 [4000–4800]	12 000 [11 000–13 000]		
New HIV infections (0–14)	<100 [<100– <100]	<100 [<100–<100]	<200 [<200– <200]		
lew HIV infections (women, 15+)	<500 [<500– <500]	<500 [<500– <500]	890 [770–1000]		
lew HIV infections (men. 15+)	660 [580–710]	4000 [3600–4300]	11 000 [10 000–12 000]		
IIV incidence per 1000 population	0.01 [0.01–0.01]	0.05 [0.04–0.05]	0.12 [0.11–0.13]		
IDS-related deaths					
IDS-related deaths (all ages)	<100	<200	760		
AIDS-related deaths (0–14)	[<100- <200] <100	[<200- <500] <100	[510–1000] <100		
NDS-related deaths (women, 15+)	[<100- <100] <100 [<100- <100]	[<100-<100] <100 [<100-<100]	[<100- <100] <200 [<200- <500]		
NDS-related deaths (men. 15+)	<100 [<100-<100]	<200 [<100- <200]	520 [<500–730]		
eople living with HIV	-	<u> </u>			
eople living with HIV (all ages)	3900 [3500–4400]	16 000 [14 000–17 000]	68 000 [61 000–76 000]		
eople living with HIV (0–14)	<100 [<100– <200]	<200 [<200–<500]	510 [<500–610]		
eople living with HIV (women, 15+)	1200 [1100–1400]	2600 [2300–3000]	6200 [5500–7000]		
People living with HIV (men. 15+)	2600 [2300–2900]	13 000 [12 000–14 000]	61 000 [55 000–68 000]		
AWS AND POLICIES		STIGMA AND DISCR	RIMINATION	J	
aws criminalizing the transmission of, non- isclosure of or exposure to HIV transmission	Yes	Percentage of women and men	•		
Criminalization of sex work	Selling sexual services is criminalized	years who report discriminatory towards people living with HIV	y attitudes		
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with health services because of their the last 12 months			
Drug use or possession for personal use is an iffence		Percentage of people living with			
Criminalization of transgender people	Neither criminalized nor prosecuted	about their HIV status without t			
aws or policies restricting the entry, stay and esidence of people living with HIV	No	VIOLENCE			
Parental consent for adolescents to access HIV esting	Yes, for adolescents younger than 18 years	than Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months 10		2008	2013
spousal consent for married women to access exual and reproductive health services	No			10	7.1
Mandatory HIV testing for marriage, work or esidence permits or for certain groups	No				

EXPENDITURES						
		Fin	ancing sources			
				International: Global Fund	International: all others	
Last available report: 2013	US\$ 17 814	US\$ 4 522 803		US\$ 3 180 753	US\$ 1 554 466	US\$ 10 319 421









Change in new HIV infections since 2010

= 174%

Change in AIDS related deaths since 2010

299%

Incidence: prevalence ratio

0.18


KEY POPULATIONS

1121 1 01 02 1110113					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	152 600	531 500	10 000	122 800	
HIV prevalence	0.6%	4.9%	29%	1.7%	
Know their HIV status		16.08%		14.68%	
Antiretroviral therapy coverage					
Condom use	70.6%	49.8%	14.5%	37.17%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	6000 [2500 –11 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	27.6%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



All ages	71%	36%	%	
All ages	[64–79%]	[33–40%]	[%]	
Children (0, 14)	18%	13%	%	
Children (0-14)	[16–22%]	[12–16%]	[%]	
107 (4 5 .)	48%	12%	%	
Women (15+)	[43–54%]	[11–14%]	[%]	
Man (451)	74%	39%	%	
Men (15+)	[66–82%]	[35-43%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

Yes

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	5%	11%
accessing antiretroviral medicines	[4–6%]	[10–14%]
Early infant diagnosis	3%	5%
Early Illiant diagnosis	[3_4%]	[4-5%]

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15–24 years (2017)

— Women	20.2%
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2013)	51.5%
Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	
Harm reduction	
— Use of sterile injecting equipment at	63.6%

last injection (2015)

person who injects

therapy

- Needles and syringes distributed per

- Safe injection rooms available (2016)

Coverage of opioid substitution

- Naloxone available (2016)

63.6%

No

No

SINGAPORE

		2010	2017
New HIV infections			
land HIV infantions (all areas)	<500	<500	<500
lew HIV infections (all ages)	[<500-<500]	[<500-<500]	[<500-<500]
lew HIV infections (0–14)			
	[]	[]	[]
lew HIV infections (women, 15+)	<100	<100	<100
ow the imposions (womon, 10-7)	[<100-<100]	[<100-<100]	[<100-<100]
land LIDV infections (many 451)	<500	<500	<500
ew HIV infections (men, 15+)	[<500-<500]	[<500-<500]	[<200-<500]
IIV incidence per 1000 population	0.11 [0.09–0.13]	0.11 [0.09–0.13]	0.08 [0.06–0.09]
IDS-related deaths			
IDO related deaths (all area)	<200	<200	<100
IDS-related deaths (all ages)	[<200-<200]	[<100- <200]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
IDC valeted deeths (warmen 451)	<100	<100	<100
DS-related deaths (women, 15+)	[<100-<100]	[<100-<100]	[<100-<100]
IDO selected designs (see a 450)	<200	<200	<100
IDS-related deaths (men, 15+)	[<100-<200]	[<100-<200]	[<100-<100]
eople living with HIV			
. •	4200	5700	7600
eople living with HIV (all ages)	[3600–4800]	[4800–6500]	[6300–8900]
People living with HIV (0–14)			
oopio iiviiig iiiii iiiv (oʻr4)	[]	[]	[]
eople living with HIV (women, 15+)	<500	590	750
copic living with the (women, 10-)	[<500–540]	[520–680]	[650–850]
People living with HIV (men, 15+)	3700	5100	6900
eopie living with Hiv (men, 13+)	[3100–4300]	[4200–5900]	[5500–8100]
AVAC AND DOLLCIES		CTICMA AND	DICCOLAINIATION
LAWS AND POLICIES		STIGMA AND I	DISCRIMINATION
aws criminalizing the transmission of, n			
isclosure of or exposure to HIV transmis	ssion	Percentage of women	and men aged 15–49

Criminalization of sex work

Criminalization of same-sex sexual acts

Criminalization of transgender people

Drug use or possession for personal use is an offence

Laws or policies restricting the entry, stay and residence of people living with HIV

Parental consent for adolescents to access HIV Yes, for adolescents younger than testing 16 years

Yes

Spousal consent for married women to access No sexual and reproductive health services

Mandatory HIV testing for marriage, work or residence permits or for certain groups

towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


		Fina	incing sources			
Domest	tic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	

Last available report: 2017 US\$ 52 093 243 US\$ 52 093 243









Change in new HIV infections = -24% since 2010

Change in AIDSrelated deaths since 2010 .44% Incidence: prevalence ratio

= 0.04


KEY POPULATIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					10 363
HIV prevalence	0%	11%	0.5%		1.1%
Know their HIV status					
Antiretroviral therapy coverage		99.2%		100%	100%
Condom use		57.8%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	44 [37–51]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	2.8%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment (2017)	99.39%
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



			7 11	
Allones	91%	77%	72%	
All ages	[75– >95%]	[64–90%]	[60–85%]	
Children (0-14)	%	%	%	
Cililateii (0–14)	[%]	[%]	[%]	
Women (15+)	%	77%	%	
women (15+)	[%]	[67–88%]	[%]	
Men (15+)	%	77%	%	
Well (15+)	[–%]	[62–91%]	[%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

- Women

— Men

Knowledge of HIV prevention among young people aged 15–24 years

— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2017)	24	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	%	%
accessing antiretroviral medicines	[%]	[%]
Early infant diagnosis	%	%
Early Illiant diagnosis	r _ %1	[_ %]


Harm reduction


Use of sterile injecting equipment at last injection	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	
— Safe injection rooms available (2016)	


SRI LANKA


EPIDEMIC ESTIMATES			
	2005	2010	2017
New HIV infections			
New HIV infections (all ages)	<500 [<500– <500]	<500 [<500– <500]	<200 [<200–<200]
New HIV infections (0–14)	 []	 [=]	 []
New HIV infections (women, 15+)	<200 [<200– <200]	<100 [<100- <100]	<100 [<100– <100]
New HIV infections (men, 15+)	<500 [<500– <500]	<200 [<200–<200]	<200 [<200– <200]
HIV incidence per 1000 population	0.02 [0.02–0.02]	0.01 [0.01–0.01]	<0.01 [<0.01–<0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500 [<200– <500]	<500 [<500– <500]	<500 [<200– <500]
AIDS-related deaths (0–14)	 []	[]	 []
AIDS-related deaths (women, 15+)	<100 [<100– <100]	<100 [<100-<100]	<100 [<100–<100]
AIDS-related deaths (men, 15+)	<200 [<200– <200]	<200 [<200– <500]	<200 [<200– <200]
People living with HIV			
People living with HIV (all ages)	4200 [3700–4900]	4200 [3600–5100]	3500 [3000–4200]
People living with HIV (0-14)	 [–]	 []	 []
People living with HIV (women, 15+)	1300 [1100–1500]	1300 [1100–1600]	1200 [1000–1400]
People living with HIV (men, 15+)	2900 [2500–3400]	2800 [2400–3500]	2300 [2000–2800]
LAWS AND POLICIES		STIGMA AND DISCR	IMINATION
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men	
Criminalization of sex work	Other punitive regulation of sex work	years who report discriminatory towards people living with HIV	v attitudes
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with health services because of their the last 12 months	
Drug use or possession for personal use is an offence	Drug use or consumption is a specific offence in law	Percentage of people living with reported a health-care profession	
Criminalization of transgender people	Neither criminalized nor about their HIV status without their cons		
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	/ No	Proportion of ever-married or power women aged 15–49 years who e	experienced
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

EXPENDITURES				
	Fin	ancing sources		
Last available report: 2013	 US\$ 671 143		 US\$ 5511	US\$ 1 226 938









Change in new HIV infections = -26% since 2010

Change in AIDSrelated deaths = since 2010

Incidence: prevalence ratio

-24%

0.05


KEY POPULATIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population		•••			
HIV prevalence	0%	1.5%	0%		0.036%
Know their HIV status					
Antiretroviral therapy coverage					100%
Condom use	93.1%	47.1%	25.9%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	20 [15–27]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	5.8%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment (2017)	100%
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed
Allagos	68%	37%	34%
All ages	[59-81%]	[32-44%]	[30-41%]
Children (0-14)	%	%	%
Cilidren (0-14)	[%]	[%]	[%]
Women (15+)	71%	35%	33%
Wolliell (15+)	[61–83%]	[30-41%]	[28–38%]
Mon (15+)	66%	37%	34%
Men (15+)	[57–80%]	[31–45%]	[29–42%]

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

No

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15–24 years

people aged 15–24 years	
— Women	
— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	74.2%

Men aged 15–49 years who are circumcised	Not applicable	
Male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2017)		

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Early infant diagnosis	%	%

Harm reduction


 Use of sterile injecting equipment at last injection (2014) 	46.3%
 Needles and syringes distributed per person who injects (2016) 	0.0
 Coverage of opioid substitution therapy 	
— Naloxone available (2016)	No
— Safe injection rooms available (2016)	No


THAILAND


			3047		
	2005	2010	2017		
lew HIV infections					
lew HIV infections (all ages)	 [–]	 [–]	 []		
lew HIV infections (0–14)	 [–]	 [–]	 []		
lew HIV intections (women, 15+)	 [–]	 [–]	 []		
lew HIV infections (men. 15+)	 [–]	 []	 []		
IIV incidence per 1000 population	[–]	[]	[]		
IDS-related deaths					
IDS-related deaths (all ages)	41 000 [34 000–49 000]	24 000 [15 000–37 000]	15 000 [11 000–22 0	00]	
AIDS-related deaths (0–14)	1100 [900–1300]	<500 [<500-<500]	<100 [<100- <100]		
AIDS-related deaths (women, 15+)	12 000 [9600–13 000]	7000 [4600–10 000]	5500 [3900–9200]		
AIDS-related deaths (men. 15+)	28 000 [23 000–35 000]	17 000 [10 000–26 000]			
eople living with HIV					
eople living with HIV (all ages)	570 000 [460 000–720 000]	510 000 [450 000–610 000]	440 000 [390 000–510	000]	
eople living with HIV (0-14)	12 000 11 000–15 000]	9000 3400 [7600–11 000] [2900–4100]			
eople living with HIV (women, 15+)	220 000 [190 000–270 000]	220 000 190 000 [190 000–260 000] [170 000–220 000]			
People living with HIV (men. 15+)	330 000 [260 000–450 000]	290 000 [250 000–350 000]	240 000 [210 000–280	000]	
AWS AND POLICIES		STIGMA AND I	DISCRIMINATIC	N	
aws criminalizing the transmission of, non- lisclosure of or exposure to HIV transmission		Percentage of women a	_	2006	2013
Criminalization of sex work			years who report discriminatory attitudes towards people living with HIV 65.3*		29.2*
Criminalization of same-sex sexual acts			Percentage of people living with HIV denied health services because of their HIV status in		
Drug use or possession for personal use is an Iffence		Percentage of people li	iving with HIV who professional told others	•	
Criminalization of transgender people		about their HIV status	without their consent		
aws or policies restricting the entry, stay and esidence of people living with HIV		VIOLENCE			
arental consent for adolescents to access HIV esting	No	Proportion of ever-mar women aged 15–49 yea			
pousal consent for married women to access exual and reproductive health services	No	physical or sexual viole intimate partner in the	ence from a male		
/landatory HIV testing for marriage, work or	No	*Female respondents or	alv.		


EXPENDITURES	

		Fina	ancing sources	International: Global	International:	
	Domestic private	Domestic public	International: PEPFAR	Fund	all others	Total
Last available report: 2013	US\$ 76 396	US\$ 256 685 666	US\$ 1 863 515	US\$ 27 326 826	US\$ 415 073	US\$ 287 278 782









Change in new HIV infections since 2010

Change in AIDS-related deaths since 2010

Incidence: prevalence ratio


KEY POPULATIONS

	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	144 000	590 700	42 000	62 800	311 587
HIV prevalence	1%	9.15%	19.02%		
Know their HIV status	58.3%			72.3%	
Antiretroviral therapy coverage					
Condom use	80.8%	82.1%	47.2%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and	10.51%				

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	10 000 [6100 –16 000]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	14%
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



	riigii status	tieatilielit	virally supplessed	
Allores	>95%	72%	62%	
All ages	[86->95%]	[63–83%]	[55–72%]	
Children (0, 44)	>95%	84%	71%	
Children (0-14)	[>95->95%]	[72->95%]	[60–86%]	
Maman (4E1)	>95%	75%	66%	
Women (15+)	[86->95%]	[65–86%]	[57–75%]	
BB (4 B s)	>95%	70%	59%	
Men (15+)	[85->95%]	[61–80%]	[52–68%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15-24 years (2016)

— Women	46%
— Men	45.1%
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner) (2017)	
— Women	76.8%
— Men	75%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	1865

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV	94%	>95%
accessing antiretroviral medicines	[76->95%]	[79->95%]
Early infant diagnosis	54%	94%
Early Illiant diagnosis	[46–66%]	[79->95%]

Harm reduction

during the reporting period (2017)

 Use of sterile injecting equipment at last injection (2014) 	84.88%
 Needles and syringes distributed per person who injects (2017) 	12.79
 Coverage of opioid substitution therapy (2017) 	4.1%
— Naloxone available (2016)	
— Safe injection rooms available (2016)	

VIET NAM

EPIDEMIC ESTIMATES					
	2005	2010	2017		
New HIV infections					
New HIV infections (all ages)	 []	 [=]	 [–]		
New HIV infections (0–14)	 []	 [–]	 []		
New HIV infections (women, 15+)	 []	 [–]	 []		
New HIV infections (men, 15+)	 []	 [=]	 [–]		
HIV incidence per 1000 population	[]	[–]	[]		
AIDS-related deaths					
AIDS-related deaths (all ages)	10 000 [8200–12 000]	8600 [6900–10 000]	8600 [6600–11 000]		
AIDS-related deaths (0–14)	<500 [<500–510]	<500 [<200–<500]	<200 [<100– <500]		
AIDS-related deaths (women, 15+)	1700 [1300–2100]	1700 [1300–2100]	1900 [1300–2500]		
AIDS-related deaths (men, 15+)	8100 [6500–9900]	6600 [5400–7700]	6600 [5100–8200]		
People living with HIV					
People living with HIV (all ages)	190 000 [170 000–220 000]	230 000 [200 000–270 000]	250 000 [220 000–280 0	000]	
People living with HIV (0–14)	2600 [2300–3000]	4100 [3400–4800]	5400 [4400–6600]		
People living with HIV (women, 15+)	46 000 [41 000–52 000]	65 000 [57 000–75 000]	79 000 [70 000–90 000)]	
People living with HIV (men, 15+)	150 000 [130 000–170 000]	160 000 [140 000–190 000]	160 000 [150 000–190 0	000]	
LAWS AND POLICIES		STIGMA AND D	ISCRIMINATIO	N	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of women an	•	2006	2014
Criminalization of sex work			years who report discriminatory attitudes towards people living with HIV 44.1*		29.2*
A fortish shows a form		Percentage of people livi			2014
Criminalization of same-sex sexual acts		health services because the last 12 months	ot their HIV status in		1.8
Drug use or possession for personal use is a offence	an	Percentage of people livi			2014
Criminalization of transgender people			reported a health-care professional told others about their HIV status without their consent		10.2

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES

Laws or policies restricting the entry, stay and

Parental consent for adolescents to access HIV

Spousal consent for married women to access

sexual and reproductive health services Mandatory HIV testing for marriage, work or


residence permits or for certain groups


residence of people living with HIV


Last available report: 2012	Bomestic private	US\$ 30 327 094	US\$ 28 917 091	Fund US\$ 19 495 015	all others US\$ 900 934	US\$ 95 446 487
Financing sources Domestic private Domestic public International: PEPFAR International: Global International: Tot. Tot.					Total	


testing

^{*}Female respondents only









Change in new HIV infections since 2010

Change in AIDSrelated deaths since 2010

0%

Incidence: prevalence ratio

= ..


KEY	\Box	DIL			10
$K \vdash Y$	20		Δ	1()1\	

RETTOTOL (HOIVS					
	Sex workers	Gay men and other men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	85 600	174 944	226 900		
HIV prevalence	3.7%	12.2%	14%		
Know their HIV status	39.6%	65.4%	61.5%		
Antiretroviral therapy coverage	27.6%	17.7%	53.4%		
Condom use	82.9%	59.9%	43.7%		
Coverage of HIV prevention programmes	32.8%	28.7%	18.7%	32.8%	
Avoidance of health care because of stigma and discrimination					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2016)	4200 [3400 –5100]
Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (2016)	
Cervical cancer screening of women living with HIV	
Proportion of people coinfected with HIV and hepatitis B virus receiving combined treatment	
Proportion of people coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



0 —				0%
-	ple living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	0 76
Allores	%	50%	43%	
All ages	[%]	[44–57%]	[38-49%]	
01:11.1(0.44)	%	88%	%	
Children (0-14)	[%]	[71->95%]	[%]	
Mamon (4F1)	%	52%	%	
Women (15+)	[%]	[46-60%]	[%]	
Man (451)	%	48%	%	
Men (15+)	[%]	[42-55%]	[–%]	

Is antiretroviral therapy provided in community settings (such as outside health facilities) for people who are stable on antiretroviral therapy?

HIV PREVENTION

— Women

Knowledge of HIV prevention among young people aged 15–24 years (2014)

demand for family planning satisfied by

— Men	
Condom use at last higher-risk sex (with a non-marital, non-cohabiting partner)	
— Women	
— Men	
Women aged 15–49 years who have their	

Men aged 15–49 years who are circumcised	Not applicable	
Male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2017)	808	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2017
Percentage of pregnant women living with HIV accessing antiretroviral medicines	44% [36–52%]	73% [61–85%]
Early infant diagnosis	%	31%

Harm reduction

modern methods

arm reduction	
 Use of sterile injecting equipment at last injection (2017) 	98%
 Needles and syringes distributed per person who injects (2016) 	147.8
 Coverage of opioid substitution therapy (2016) 	22.19%
— Naloxone available (2016)	
— Safe injection rooms available (2016)	

49.3%



METHODS

Methods for deriving UNAIDS estimates

INTRODUCTION

UNAIDS annually provides revised global, regional and country-specific modelled estimates using the best available epidemiological and programmatic data to track the HIV epidemic. Modelled estimates are required because it is impossible to count the exact number of people living with HIV, people who are newly infected with HIV or people who have died from AIDS-related illness in any country: doing so would require regularly testing every person for HIV and investigating all deaths, which is logistically impossible and ethically problematic. Modelled estimates—and the lower and upper bounds around these estimates—provide a scientifically appropriate way of describing HIV epidemic levels and trends.

PARTNERSHIPS IN DEVELOPING METHODS FOR UNAIDS ESTIMATES

Country teams use UNAIDS-supported software to develop estimates annually. The country teams are primarily comprised of demographers, epidemiologists, monitoring and evaluation specialists, and technical partners.

The software used to produce the estimates is Spectrum, which is developed by Avenir Health, and the Estimates and Projections Package, which is developed by the East–West Center.¹ The UNAIDS Reference Group on Estimates, Modelling and Projections provides technical guidance on the development of the HIV component of the software.²

A BRIEF DESCRIPTION OF METHODS USED BY UNAIDS TO CREATE ESTIMATES

For countries where HIV transmission is high enough to sustain an epidemic in the general population, available epidemiological data typically consist of HIV prevalence results from pregnant women attending antenatal clinics and from nationally representative population-based surveys. Many countries have historically conducted HIV sentinel surveillance among women attending antenatal clinics, which requires collecting data from a selection of clinics for several months every few years. More recently, many countries have stopped conducting sentinel surveillance and are now using the data from

the routine HIV tests conducted when pregnant women at antenatal clinics are tested as part of programmes for the prevention of mother-to-child transmission. These data avoid the need to conduct a separate surveillance effort, and they provide a complete set of data from all clinics instead of samples from specific sites.

The prevalence trends among pregnant women at antenatal clinics, whether determined from surveillance or routine data, can be used to inform estimates of national prevalence trends, whereas data from population-based surveys—which are conducted less frequently but have broader geographical coverage and also include men—are more useful for informing estimates of national HIV prevalence levels. Data from these surveys also contribute to estimating age- and sex-specific HIV prevalence levels and trends. For a few countries in sub-Saharan Africa that have not conducted population-based surveys, HIV prevalence levels are adjusted based on comparisons of antenatal clinic surveillance and population-based survey data from other countries in the region. HIV prevalence trends and numbers of people on antiretroviral therapy are then used to derive an estimate of HIV incidence trends.

Historically, countries with high HIV transmission have produced separate HIV prevalence and incidence trends for rural and urban areas when there are well-established geographical differences in prevalence. To better describe and account for further geographical heterogeneity, an increasing number of countries have produced subnational estimates (e.g. at the level of the province or state) that, in some cases, also account for rural and urban differences. These subnational or rural-urban estimates and trends are then aggregated to obtain national estimates.

In the remaining countries, where HIV transmission largely occurs among key populations at higher risk of HIV and the epidemic can be described as low-level, the estimates are derived from either surveillance among key populations and the general low-risk population, or from HIV case reporting data, depending on which data are most reliable in a particular country. In countries with high-quality HIV surveillance data among the key populations, the data from repeated HIV prevalence studies focused on key populations are used to derive

¹ More information on Avenir Health can be found at www.avenirhealth.org. The East–West Center website can be found at www.eastwestcenter.org.

² For more on the UNAIDS Reference Group on Estimates, Modelling and Projections, please visit www.epidem.org.

national estimates and trends. Estimates of the size of key populations are increasingly derived empirically in each country; when studies are not available, they are derived based on regional values and consensus among experts. Other data sources—including HIV case reporting data, population-based surveys and surveillance among pregnant women—are used to estimate the HIV prevalence in the general low-risk population. The HIV prevalence curves and numbers of people on antiretroviral therapy are then used to derive national HIV incidence trends.

For most countries in western and central Europe and North America—and many countries in Latin America, the Caribbean and the Middle East and North Africa that have insufficient HIV surveillance or survey data, but which have robust disease reporting systems—HIV case reporting and AIDS-related mortality data from vital registration systems are used directly to inform trends and levels in national HIV prevalence and incidence. These methods also allow countries to take into account evidence of underreporting or reporting delays in HIV case report data, as well as the misclassification of deaths from AIDS-related illness.

In all countries where UNAIDS supports the development of estimates, assumptions about the effectiveness of HIV programme scale-up and patterns of HIV transmission and disease progression are used to obtain age- and sex-specific estimates of (a) people living with HIV, (b) people newly infected with HIV, (c) people dying from AIDS-related illness and (d) other important indicators (including treatment programme coverage statistics). These assumptions are based on systematic literature reviews and analyses of research study data by scientific experts. Demographic population data, including fertility estimates, are derived from the United Nations Population Division's World Population Prospects 2017 data.

Selected inputs into the model—including the number of people on antiretroviral therapy and the number of women accessing services for the prevention of mother-to-child transmission of HIV by type of regimen—are reviewed and validated in partnership with the United Nations Children's Fund (UNICEF), the World Health Organization (WHO), the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), and selected technical partners.

Final country-submitted files containing the modelled outputs are reviewed at UNAIDS to ensure that the results are comparable across regions and countries and over time.

UNCERTAINTY BOUNDS AROUND UNAIDS ESTIMATES

The estimation software calculates uncertainty bounds around each estimate. These bounds define the range within which the true value lies (if it can be measured). Narrow bounds indicate that an estimate is precise, while wide bounds indicate greater uncertainty regarding the estimate.

In countries using HIV surveillance data, the quantity and source of the data available partly determine the precision of the estimates: countries with more HIV surveillance data have smaller ranges than countries with less surveillance data or smaller sample sizes. Countries in which a national population-based survey has been conducted generally have smaller ranges around estimates than countries where such surveys have not been conducted, while countries producing subnational estimates at the provincial level have wider ranges. In countries using HIV case reporting and AIDS-related mortality data, the number of years of data and the magnitude of the cases reported or the deaths from AIDS-related illness observed will contribute to the precision of the estimate.

The assumptions required to arrive at the estimate also contribute to the width of the ranges around the estimates: in brief, the more assumptions that are made, the wider the uncertainty range, since each assumption introduces additional uncertainties. For example, the ranges around the estimates of adult HIV prevalence are smaller than those around the estimates of HIV incidence among children, which require additional data on prevalence among pregnant women and the probability of mother-to-child HIV transmission, each of which have their own additional uncertainty.

UNAIDS is confident that the actual numbers of people living with HIV, people who are newly infected with HIV or people who have died from AIDS-related illness lie within the reported ranges. Over time, more and better data from countries will steadily reduce uncertainty.

IMPROVEMENTS TO THE 2018 UNAIDS ESTIMATES MODEL

Country teams create new Spectrum files every year. The files may differ from one year to the next for two reasons. First, new surveillance and programme data are entered into the model; this can change HIV prevalence and incidence trends over time, including for past years.

Second, improvements are incorporated into the model based on the latest available science and statistical methods that lead to the creation of more accurate trends in HIV incidence. Due to these improvements to the model and the addition of new data to create the estimates, the results from previous years cannot be compared with the results from this year. However, a full historical set of estimates are created each year, enabling a description of trends over time.

Between the previous estimates and the 2018 estimates, the following changes were applied to the model under the guidance of the UNAIDS Reference Group on Estimates, Modelling and Projections and based on the latest scientific evidence.

- Demographic data in the models were updated from the World Population Prospects 2015 estimates to the 2017 estimates.
- Assumptions about retention on antiretroviral therapy among pregnant women living with HIV were included.
- Aggregate routine data on prevalence among women attending antenatal clinics are now used to estimate the number of women living with HIV who are giving birth.
- Assumptions about the trends in HIV prevalence among pregnant women versus trends among the general population were updated.
- Annual HIV mortality probabilities among people on treatment in western and central Europe and North America were revised based on a special analysis conducted by the Antiretroviral Therapy Cohort Collaboration.
- An option was added in the model to prioritize allocation of treatment to individuals with the lowest CD4 count who had not yet initiated treatment.
- A new approach to fitting more complex incidence patterns for countries using case reporting and vital registration data is available.
- New methods to estimate the proportion of people dying before diagnosis and time from infection to diagnosis were incorporated into the model for countries using case reporting data to estimate incidence.

More detailed information on revisions to the 2018 model and Spectrum generally can be found at www.epidem. org.

MEASURING ANTIRETROVIRAL THERAPY COVERAGE

Since 2013, UNAIDS has provided the number and estimates of the proportion of all adults and children living with HIV who are on antiretroviral therapy (as opposed to those eligible for therapy according to national or international guidelines). This approach to estimating coverage reflects the WHO recommendations of starting antiretroviral therapy among everyone diagnosed as HIV-positive.

Countries report the number of people on treatment through the Global AIDS Monitoring (GAM) tool and Spectrum. Although those values come through routine data, they are likely to have some level of uncertainty if the country cannot deduplicate individuals who might receive medication from two different clinics or if there are delays in reporting data. Using results from data quality reviews through 2016, an estimated uncertainty—0.88 and 1.04 for the lower and upper bounds, respectively—was added to the number of people on treatment at the regional and global levels.

PUBLICATION OF COUNTRY-SPECIFIC ESTIMATES

UNAIDS aims to publish estimates for all countries with populations of 250 000 or more in 2017. For countries with populations of 250 000 or more that did not submit estimates, UNAIDS developed estimates using the Spectrum software that were based on published or otherwise available information. These estimates contributed to regional and global totals but were not published as country-specific estimates.

In countries with low-level epidemics, the number of pregnant women living with HIV is difficult to estimate. Many women living with HIV in these countries are sex workers or people who use drugs—or they are the sexual partners of gay men and other men who have sex with men or people who use drugs—making them likely to have different fertility levels than the general population. UNAIDS does not present estimates of mother-to-child HIV transmission, including estimates related to children in some countries that have concentrated epidemics, unless adequate data are available to validate these estimates. UNAIDS also does not publish these estimates for countries where the estimated number of pregnant women living with HIV is less than 100.

With regard to reporting incidence trends, if there are not enough historical data to state with confidence whether a decline in incidence has occurred, UNAIDS does not publish data other than that from the most recent year; this prevents users from making inaccurate inferences about trends. Specifically, incidence trends are not published if there are fewer than four data points for the key population or if there have been no data for the past four years for countries using repeated survey or routine testing data. Trends prior to 2000 are not published for countries using case surveillance models if there is no early case surveillance or mortality data available.

Finally, UNAIDS does not publish country estimates when further data or analyses are needed to produce valid estimates. More information on the UNAIDS estimates and the individual Spectrum files for most countries can be found on the UNAIDS website (www. unaids.org). Resulting estimates can be found in the Aidsinfo section of the UNAIDS website (http://aidsinfo.unaids.org/).

Methods for deriving the 90-90-90 targets

INTRODUCTION

Starting in 2016, UNAIDS has provided estimates of global, regional and country-specific progress against the 90–90–90 targets. Progress towards these targets is directly monitored using three basic indicators:

- Indicator 1 (the first 90): the percentage of all people living with HIV who know their HIV status.
- Indicator 2 (the second 90): the percentage of people who know their HIV-positive status and are accessing treatment.
- Indicator 3 (the third 90): the percentage of people on treatment who have suppressed viral loads.

Metrics related to Indicators 2 and 3 can also be expressed as a percentage of all people living with HIV. When numbers or coverage of the treatment target are expressed relative to the total number of people living with HIV, this is called the "HIV testing and treatment cascade." Using this approach, the second and third targets of the 90–90–90 targets translate into 81% coverage of antiretroviral therapy and 73% of people achieving viral suppression by 2020.

UNAIDS published its first set of global and regional testing and treatment cascades in 2015. Estimates of antiretroviral therapy coverage among people living with HIV are available going back to when treatment was first introduced. Results presented in this report supersede the previously published 2015 and 2016 values.

Since 2015, UNAIDS has also tracked progress towards the 90–90–90 targets by monitoring viral load testing access among people on treatment. If most people in the country are receiving a viral load test annually, as

recommended by WHO, we can have confidence in the accuracy of the estimate of viral suppression among all people living with HIV.

METHODS FOR MEASURING THE 90–90–90 TARGETS

To describe country-level progress against the 90–90–90 targets, UNAIDS analysed data on the number of people who knew their HIV status, the number of people on treatment and the number of people who were virally suppressed among those tested, as reported through the GAM tool and Spectrum.

A description of the GAM system and the treatment target-related indicators that countries report against are provided in the UNAIDS GAM 2018 guidelines (1). All programme data submitted to UNAIDS—including the number of people reported to know their status, the number of people accessing treatment and the number of people on treatment who are virally suppressed—were validated by UNAIDS and its partners prior to publication.

Country-submitted data that did not meet the required validation checks for quality either at the indicator level or across the treatment cascade were not published. Not all countries were able to report against all three prongs of the 90–90–90 targets.

The final set of country measures of progress against the 90–90–90 targets for 2015 through 2017 are available at http://aidsinfo.unaids.org. Complete treatment cascades were available for 53 countries in 2017. Upper and lower ranges of uncertainty for country-level estimates were calculated from the range of estimated numbers of people living with HIV. This range may not fully capture uncertainty in the reported programme data.

To estimate regional and global progress against the 90-90-90 targets, UNAIDS supplemented the country-supplied data submitted through GAM with data obtained from a review of other published and unpublished data sources, including grey literature and Demographic and Health Survey results. There were insufficient reported data from countries in western and central Europe and North America in 2017 to present results for the region, although the country values that were available in the region were used to construct the global totals. Upper and lower ranges of uncertainty for global and regional estimates were calculated from the range of numbers of people living with HIV and the lower and upper ranges of the numbers of people on treatment in the region. This range may not fully capture uncertainty in the reported or missing programme data for the first and third indicators.

DATA SOURCES AND INDICATOR-SPECIFIC METHODS FOR DERIVING GLOBAL AND REGIONAL METHODS

Estimates of people living with HIV

Unless otherwise stated, all progress measures in this report are based on UNAIDS global, regional and country-specific modelled estimates of the numbers of people living with HIV from Spectrum. Estimates of people living with HIV were available for 169 countries. More details about how UNAIDS derives estimates and uncertainty bounds around the number of people living with HIV and those accessing antiretroviral therapy can be found under "Measuring antiretroviral therapy coverage" (above, in Part 1 of this annex).

Knowledge of HIV status among people living with HIV

Global and regional measures of the number of people living with HIV who know their status were derived using the most recent HIV surveillance, programme data, nationally representative population-based survey data and modelled estimates for 102 countries in 2017. Where data were available separately for children (aged 0–14 years) and adults (aged 15 years and older), age-specific measures were first calculated and then aggregated to produce a national measure.

For 80 countries in 2017, the number of people living with HIV who knew their HIV status is based on HIV surveillance systems, programme registers or modelled estimates derived from case surveillance and programme data. If the measure from these sources was lower than the number of people accessing antiretroviral

therapy, the reported value was excluded from the analysis and replaced by a regionally-derived estimate. For countries using HIV surveillance or programme data, a country's measure was included only if the HIV surveillance system had been functioning since before 2008. Countries with more recent systems may not have captured all people living with HIV who were diagnosed prior to 2008.

Although HIV surveillance systems, including those based on programme registers, can be a reasonably robust source of data to estimate the number of people living with HIV who know their status, biases in the reported numbers may still exist. For example, a country's measure of the knowledge of status may be underestimated if not all people diagnosed are reported to the surveillance system in a timely manner; the measure also may be overestimated if people are reported to the system or included on a register more than once and these duplicates are not detected. Similarly, if people die or emigrate but are not removed from the system, the number of people living with HIV who are reported to know their HIV status also will be overstated.

The estimated numbers of people living with HIV who knew their status for 14 countries in sub-Saharan Africa in 2017 were derived from nationally representative population-based surveys conducted since 2011 and from treatment data reported through GAM. Four countries with surveys through 2017 directly asked respondents who tested HIV-positive whether they knew their HIV status as part of the survey, and this proportion was applied to the total number of people estimated to be living with HIV in the country. In the remaining 10 countries with a survey that did not directly ask participants about knowledge of their HIV status, a stepwise approach was used to estimate knowledge of status.

In the first step, the total percentage of people who could know their status in the year of the most recent survey is estimated. For adults, this percentage is estimated by calculating the percentage of those who tested HIV-positive in the survey who had reported ever having been tested for HIV and had received the last test result. For children, who are not included in the survey, a proxy measure of treatment coverage in the survey year is used to estimate knowledge of status among children. This is a conservative measure, as some children may not have initiated treatment. To estimate knowledge of status for all people in the

year of the survey, the child and adult estimates are combined, weighted by the numbers of children and adults living with HIV.

- In the second step, the percentage of people who could know their status in the current or previous reporting year is derived by projecting the results from the first step forward. To do this, an assumption is made that the rate of testing scale-up in the era of test-and-treat was the same as the rate of scale-up of people starting treatment, calculated by the percentage point difference in total treatment coverage (for both adults and children) between the survey year and the treatment coverage value for either the current or previous year. For surveys conducted in 2017, the 2015 and 2016 values are estimated for previous years using a similar process as the one described above.
- In the third step, the estimate of people living with HIV who know their status for the year is derived by using the midpoint between the percentage of people living with HIV who could know their status (i.e. the second step) and the percentage of people living with HIV on treatment.

The measurement of knowledge of HIV status based on survey data when participants are not directly asked if they know their HIV status has several limitations. Typically, estimates derived from these surveys will underestimate knowledge of status for three reasons:

- In settings where stigma and discrimination is or has been high, people may be reluctant to disclose that they have ever tested for HIV and received their results.
- People who report ever testing may have seroconverted after their last test result and are therefore incorrectly counted as aware of their HIV status.
- 3. Most surveys that do not directly ask respondents about their HIV status occurred prior to 2017. Although surveys conducted prior to 2011 were excluded, it is possible that the adjustment method based on treatment scale-up does not accurately capture increases in the knowledge of status that occur over time among people living with HIV.

Underestimation of the reported number of people living with HIV who know their status can also occur in countries where survey respondents are directly asked about their HIV status. In these instances, the risk is that survey participants do not disclose their HIV status to interviewers and are incorrectly classified as unaware of it. While it is impossible to measure the exact magnitude of this bias, in previous surveys in Kenya, Malawi and Uganda, anywhere from one tenth to one third of HIV-positive participants misreported their HIV status as negative (2). Underestimation of knowledge of status also can occur at the national level if people living with HIV learn their status either as a result of—or subsequent to—the survey, although this proportion of the total number of people in a country who know their status will be small.

For 34 countries without a current measure of knowledge of status in 2017, UNAIDS used published and unpublished grey literature and historical estimates reported through GAM to inform the regional and global values. A similar method used to project estimated knowledge of status for direct surveys from historical data was applied to estimates from such countries before 2017.

For 40 countries without any estimate of the number of people living with HIV who know their status—countries that are home to just 8% of the total estimated number of people living with HIV worldwide—the regional average of the ratio of the number of people who know their status and the number on treatment was calculated from available data submitted by countries in the region and weighted according to the number of people living with HIV by country. Knowledge of status was capped at 95%. The total number of people estimated to know their HIV status in countries was added across the region and globally to construct the numerator of the first 90 and the denominator of the second 90.

People accessing antiretroviral therapy

Global and regional measures of antiretroviral therapy numbers are calculated from country-reported programme data through GAM and the UNAIDS-supported Spectrum software. For a small number of countries where reported numbers of people on treatment are not available—primarily in western and central Europe and North America—estimates of the number of people on treatment are developed either in consultation with the public health agency responsible for monitoring the national treatment programme or based on published sources.

In partnership with UNICEF, WHO and other partners that support treatment service delivery in countries,

UNAIDS reviews and validates treatment numbers reported through GAM and Spectrum on an annual basis. UNAIDS staff also provide technical assistance and training to country public health and clinical officers to ensure the quality of the treatment data that are reported. Nevertheless, this measure may overestimate the number of people on treatment if people who transfer from one facility to another are reported by both facilities. Similarly, coverage may be overestimated if people who have died, disengaged from care or emigrated are not identified and removed from treatment registries. Treatment numbers also may be underestimated if not all clinics report the numbers on treatment completely or in a timely manner.

In 2016, UNAIDS completed a triangulation of data to verify the UNAIDS global estimate of people accessing antiretroviral therapy at the end of 2015. In 2018, UNAIDS has partnered with WHO, the Global Fund, selected technical partners and ministries of health in 28 countries (most in sub-Saharan Africa) to conduct data quality reviews of reported treatment numbers. For more details about how confident UNAIDS is in reported treatment numbers, please see *How many people living with HIV access treatment?*³

People who have achieved viral suppression

Progress towards the viral suppression target among people on treatment and as a proportion of all people living with HIV is derived from data reported to GAM. For the purposes of reporting, the threshold for suppression is a viral load of less than 1000 copies per ml, although some countries may set lower thresholds or require persons to achieve an undetectable viral load. This guidance also specifies that only a person's last test result from the reporting year be submitted, so the reported number suppressed among those tested should represent people and not tests performed.

UNAIDS GAM 2018 guidelines were updated from those of 2017 to include a threshold for reporting viral load suppression outcomes, such that testing coverage should be accessible to all or nearly all (>90%), or that it is nationally representative of people on treatment (typically 50–90% testing coverage). For countries with nationally representative but not universally accessible access to treatment, the estimate of viral suppression among those tested (i.e. the third 90) was multiplied by the number of people on treatment nationally to obtain overall viral suppression levels in the country.

Based on the more stringent coverage threshold, 67 countries reported viral load suppression data from case-based surveillance or laboratory-based reporting systems in 2018 (compared with 88 in 2017). Five countries had estimates based on nationally representative population-based surveys, where viral load testing was done only among those who self-reported that they were on treatment.

Estimates for the remaining countries were constructed using the regional average of the number of people on antiretroviral therapy who are virally suppressed, weighted according to the number of people on treatment in a country. The total number of people suppressed was added across the region and globally to construct the third 90 and the overall estimate of viral suppression among people living with HIV. The same approach also was used to construct historical regional and global estimates.

A number of challenges exist in using country-reported data to monitor the viral load suppression target.

- Routine viral load testing may not be offered at all treatment facilities, and those facilities where it is offered may not be representative of the care available at facilities without viral load testing. By assuming that the percentage of people suppressed among those accessing viral load testing is representative of all people on treatment in countries with incomplete viral load testing uptake, the measure may be either overestimated or underestimated depending on the characteristics of the reporting clinics where testing is available.
- Reported access to viral load testing varies considerably across each region, and it is difficult to know whether the experience in countries that reported data to UNAIDS is similar to that of countries in the same region that did not report data. In western and central Africa, for example, only 7 of 14 countries reported estimates of viral load suppression in 2017, representing just 14% of all people on treatment in the region. In Asia and the Pacific, nationally representative estimates of viral load suppression are not available for China and India in 2017. As a result, estimates for that region are constructed based on the remaining guarter of all people accessing treatment in the region where viral load suppression data are available.

³This document is available at http://www.unaids.org/en/resources/documents/2016/how-many-people-living-with-HIV-access-treatment.

- UNAIDS guidance requests routine (annual) viral load testing results only for people who are on treatment and eligible for testing. If people newly initiated on treatment achieve viral suppression but have not yet been offered viral load testing, they will be incorrectly classified as not suppressed and the resulting viral suppression estimate will be understated. UNAIDS also requests that countries only report results from routine viral load testing; if countries report test results that are primarily performed because of suspected treatment failure, the number of people virally suppressed in these countries will be underestimated. UNAIDS validates
- country submissions for quality, but it is not always possible to identify cases where both routine and other types of testing are occurring.
- UNAIDS guidance recommends reporting viral load test results only for people on antiretroviral treatment; persons who naturally suppress the virus and are not on treatment will not be included in this measure.

As access to viral load testing coverage expands and routine monitoring systems are strengthened to compile and report these data, the ability to quantify and eventually reduce bias in the 90–90–90 targets will improve.

Distribution of new HIV infections by subpopulation

The distribution of new HIV infections by region was estimated based on data for 169 countries using five data sources.

For countries that model their HIV epidemic based on data from subpopulations, including key populations, the numbers of new infections were extracted from Spectrum 2017 files. This source provided data for sex workers from 58 countries, for people who inject drugs from 36 countries, for gay men and other men who have sex with men from 56 countries, and for transgender people from 15 countries (all of which were located in Latin America, the Caribbean and Asia). Additionally, 21 countries (mostly from Asia) had data from clients of sex workers.

The second source was mode of transmission studies conducted in countries between 2006 and 2012. The proportions of new infections estimated for each subpopulation, calculated by modes of transmission analyses, were multiplied by the number of total new gender-specific adult infections (among those aged 15–49 years) to derive an estimated number of new infections by subpopulation. This source provided data for sex workers from 18 countries, for people who inject drugs from 25 countries, and for gay men and other men who have sex with men from 22 countries.

New HIV infections for European countries with neither of the aforementioned data sources were derived from

the European Centre for Disease Prevention and Control (ECDC) and World Health Organization Regional Office for Europe HIV/AIDS surveillance in Europe 2017–2016 data (3). The proportions of new diagnoses for each region in Europe (West, central and East) were applied to UNAIDS estimates of new infections in each country for people who inject drugs and gay men and other men who have sex with men. Data for sex workers were not available from the ECDC report. New HIV infections in China, the Russian Federation and the United States were taken from the most recent available national reports of new diagnoses.

New HIV infections among countries without a direct data source were calculated from regional benchmarks. The benchmarks were set by the median proportion of new infections in the specific subpopulation in all available countries in the same region. The majority of these countries were located in sub-Saharan Africa. There were 73 countries that used benchmark values for the sex work estimate, 95 countries for the people who inject drugs estimate, 33 countries for the gay men and other men who have sex with men estimate, and 36 countries for the transgender people estimate.

The calculated proportions of infections for each key population include the sex partners of members of key populations. New infections among sex partners of key populations were estimated using the number of sex partners and transmission probabilities from the literature.

References

- 1. Global AIDS monitoring 2018: indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva: UNAIDS; 2018 (http://www.unaids.org/sites/default/files/media_asset/2017-Global-AIDS-Monitoring_en.pdf).
- 2. Johnston LG, Sabin ML, Prybylski D, Sabin K, McFarland W, Baral S et al. Policy and practice: the importance of assessing self-reported HIV status in bio-behavioural surveys. Bull World Health Organ. 2016;94:605–12.
- 3. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe. HIV/AIDS surveillance in Europe 2017–2016 data. Stockholm: ECDC; 2017.

Copyright: © 2018

Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. UNAIDS does not warrant that the information published in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

UNAIDS/JC2924/Asia and the Pacific



ASIA AND THE PACIFIC

UNAIDS Joint United Nations Programme on HIV/AIDS

20 Avenue Appia 1211 Geneva 27 Switzerland

+41 22 791 3666

unaids.org